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USE OF MULTINATIONAL REGISTRIES TO ASSESS AND COMPARE 
OUTCOMES OF PATIENTS WITH AN ACUTE CORONARY SYNDROME A 
Dissertation Presented 
 
By 
 
Hamza Awad, M.D., M.S. 
Abstract 
Background  
Acute coronary syndromes (ACS) are a major cause of mortality and morbidity in the 
developed world. By 2020, ACS will be the leading cause of morbidity and mortality 
worldwide, largely due to substantial increases in ACS burden in developing countries. 
The developing world has been under-represented in international ACS registries. The 
Arabian Gulf area is a part of the developing world where little is known about the 
epidemiology of ACS. The first aim of the dissertation is to compare ACS patient 
characteristics, current practice patterns, and in-hospital outcomes in the Arabian Gulf 
area to a large multinational sample. 
Patients with an ACS suffer numerous clinical complications that worsen their prognosis. 
Cardiogenic shock (CS) is the most serious complication of ACS and the leading cause of 
in-hospital death. Despite advances in therapies; CS hospital mortality rates continue to 
exceed 50%. The second aim of the dissertation is to describe the characteristics of 
patients presenting with ACS complicated by cardiogenic shock, their management, and 
outcomes in a large multinational sample.  
In recent years, ACS has been increasingly affecting younger patients. While marked 
age-related differences have been observed in the risk of developing as well as the 
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prognosis of ACS, few studies however examined time trends in the epidemiology of 
ACS in young adult patients. The third aim of the dissertation is to examine trends in 
frequency rates, patient characteristics, treatment practices, and outcomes in young adults 
hospitalized with an ACS.  
Methods  
Data from two large multinational registries of patients hospitalized with an ACS were 
used for this investigation. Nearly 65,000 patients were enrolled in the Global Registry of 
Acute Coronary Events (GRACE) between 2000 and 2007, while 6,700 patients 
participated in the Gulf Registry of Acute Coronary Events (Gulf RACE) in 2007. 
Results  
Aim1: Patients in Gulf RACE were significantly younger and were more likely to be 
male, diabetic, and smoke Compared to GRACE. Patients in Gulf RACE were less likely 
to receive evidence based therapies. Short-term mortality rates were comparable between 
the two patient cohorts.  
Aim2: Compared to patients with no CS, patients with CS were more likely to be older, 
female, have a history of diabetes, and heart failure. Patients with CS were less likely to 
receive effective cardiac catheterization and adjunctive cardiac medications. In-hospital 
case-fatality rate of patients with CS were 59.4%. While in-hospital mortality declines 
over the study period, incidence rates only showed minor declines. 
Aim2: Baseline characteristics of patients < 55 years of age did not significantly change, 
while the use of evidence based therapies increased significantly during the years under 
vii 
 
 
study. Rates of short-term adverse outcomes and mortality significantly declined over 
time.  
Conclusions  
We observed marked regional differences in the risk profile, clinical management, and 
outcomes of patients with an ACS internationally compared to the Arab Middle East. 
Despite the encouraging trends in the use of evidence based therapies which have likely 
contributed to the improving trends in the prognosis of ACS, rates of development of 
ACS, as well as mortality due to ACS complications, remain high. 
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 CHAPTER I 
Introduction 
1.1 Specific Aims 
Acute coronary syndromes (ACS), which include ST segment elevation myocardial 
infarction (STEMI), non-ST segment elevation myocardial infarction (NSTEMI),  and 
unstable angina (UA), are a major cause of mortality and morbidity in the developed 
world1. Each year, approximately 6.3 million people worldwide suffer an acute myocardial 
infarction (AMI), of whom 25% die as a result2. By 2020, ACS will be the leading cause of 
morbidity and mortality worldwide, largely due to substantial expected increases in the 
incidence of ACS in developing countries. Despite the importance of ACS as a global 
public health problem, little reliable data are available about changing trends in the 
prevalence and “real-world” management of patients with an ACS.  
Further investigation is needed to more fully understand the use of various 
management practices in patients hospitalized with an ACS as well as the natural history 
and long-term outcomes of these high risk patients and changing trends therein. Relatively 
few studies on ACS patients have collected post-discharge data. Furthermore, few data are 
available regarding contemporary and changing trends in post-discharge outcomes in 
patients with ACS.   
Patients with an ACS suffer numerous clinical complications that worsen their 
prognosis. Cardiogenic shock carries the worse prognosis among all clinical complications 
being the most common cause of in-hospital death in patients with ACS. Reported 
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incidence rates range from remained relatively constant over the past decade. Despite 
advances in medical treatment, revascularization techniques and mechanical support; 
cardiogenic shock continues to have devastating outcomes with hospital mortality rates 
exceeding 50%. 
Population-based registries are a valuable tool for providing information on disease 
burden, clinical practices, and outcomes. A number of coronary heart disease registries 
around the world have helped identify optimal therapeutic strategies in an attempt to 
improve the outcomes of patients hospitalized with an ACS .The GRACE (Global Registry 
of Acute Coronary Events) is the largest multinational, prospective study of clinical 
management practices and patient outcomes across the full spectrum of ACS. The GRACE 
registry provides insights into the therapeutic options used and the relationship between 
processes of care and the clinical decision-making process with various hospital and post 
discharge outcomes. GRACE includes representative hospitals in North America, South 
America, Europe, Asia, Australia and New Zealand. It is one of the few registries that have 
followed patients after hospital discharge for an ACS, further contributing to our 
understanding of long-term outcomes of ACS patients. 
Although developing countries will likely be the major contributors to the 
increasing burden of CHD over the next several decades, they have been poorly 
represented in multinational studies of CHD to date. The Arabian Gulf area (also known as 
the Persian Gulf) in particular and the Middle East in general, is a great example of 
developing countries that have seen limited CHD survey efforts. Little is known about the 
magnitude and forms of ACS that exist in the Arabian Gulf area. Additionally, there is a 
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lack of knowledge concerning the ACS related clinical practices and outcomes in that 
unique population. Recent evidence indicates an increased risk of ACS among the Gulf 
population with a high prevalence of diabetes, obesity, and smoking. The Gulf RACE 
(Gulf Registry of Acute Coronary Events) is the first completed registry designed to assess 
the actual incidence of ACS in the Arabian Gulf area and related clinical practices in an 
uncontrolled real-life setting. 
The aims of my proposed project are compare the disease characteristics of ACS in 
the Arabian Gulf area to a multinational sample, to investigate the characteristics, 
management and outcomes of patients with cardiogenic shock, and to report on time trends 
in frequency, management and outcome of young adult patients presenting with an ACS. 
For purposes of this dissertation, I will utilize data from two multinational ACS studies: 
GRACE and Gulf RACE. 
 
 Aim 1: is to compare ACS patients in the Arabian Gulf area (Gulf RACE) to a sample of 
ACS patients from a large multinational study (GRACE) in terms of patient demographics, 
clinical characteristics, current practice patterns, and in-hospital outcomes. The secondary 
objective is to compare in-hospital mortality rates and identify factors associated with 
mortality that may differ in the 2 hospitalized cohorts. 
 
Aim 2: is to describe the demographic and clinical characteristics of patients presenting 
with ACS complicated by cardiogenic shock, their management, and outcomes in a large 
multinational sample (GRACE). The secondary objective is to identify factors associated 
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with increased mortality among patients with ACS complicated by cardiogenic shock. 
Cardiogenic shock remains the main cause of in-hospital mortality among ACs patients 
and despite advances in diagnosis and management continues to have high mortality rates 
exceeding 50%. 
Aim 3: is to examine trends in frequency rates, patient characteristics, hospital treatment 
practices, and short-term outcomes in comparatively young adults (<55 years old) who had 
been hospitalized with an ACS.  
 
1.2 Background and Significance 
 
1.2.1 Scope of the Problem of ACS 
Coronary heart disease (CHD) is the leading cause of morbidity and mortality in 
the United States and developing countries3. By 2020, it is projected that mortality from 
CHD will more than  double the present mortality from this disease and CHD will be the 
single largest global cause of morbidity and mortality. Developing countries will be a 
major contributor to this increase2. These increases are taking place despite aggressive 
campaigns for prevention, advances in drug therapy, and increasing application of 
coronary reperfusion and revascularization approaches. Given the aging of the world’s  
population, and the ongoing epidemics of diabetes and obesity, these ongoing changes  will 
further expand the healthcare burden of atherosclerosis, both in developing countries as 
well as globally4. 
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 Acute coronary syndrome (ACS) is a common manifestation of underlying CHD. 
ACS is defined as a set of symptoms and signs compatible with acute myocardial ischemia 
which results from coronary artery disease. It is an umbrella term that encompasses 
unstable angina in addition to the two subtypes of acute myocardial infarction (AMI), ST-
segment elevation myocardial infarction and non ST-segment elevation myocardial 
infarction.  
  
1.2.2 Multinational ACS Survey Efforts 
 
Management of ACS is complicated involving a series of diagnostic and 
therapeutic decisions, invasive and noninvasive interventions5, 6. In the past 30 years, 
significant progress has been made in the development of effective treatment strategies for 
patients diagnosed with an ACS. Before the 1990s relatively little reliable data were 
available about the prevalence of ACS, routine management of ACS, and  the extent to 
which advanced treatments and strategies are used in daily clinical practice. Most of the 
data available during this period were derived from clinical trials. It is hard to extrapolate 
data from clinical trials to the ‘real-world’ due to their highly controlled environment, 
highly selected populations with little representation of the elderly and patients with 
comorbidities. The lack of information in “real world” settings has given rise to the 
development of ACS registries to allow better interpretation of the results of clinical trials 
and the effectiveness of treatments and procedures 7, 8. Several multinational ACS registry 
studies have been conducted in patients with unstable angina and AMI. Among the large 
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multinational registries were the Multinational MONItoring of trends and determinants in 
CArdiovascular disease(MONICA)1  project,  the Organisation to Assess Strategies for 
Ischemic Syndromes (OASIS registry)9, and The European Network for Acute Coronary 
Treatment (ENACT) study10. None of these registries, however, have provided insights 
into the relationship between processes of care and patient outcomes, or the clinical 
decision-making process. The Global Registry of Acute Coronary Events (GRACE) 
registry is the largest multinational study that covers the full spectrum of patients 
hospitalized with an ACS. It is also one of the few registries that studies post-discharge 
outcomes11, 12. Results from the GRACE study have enhanced the understanding of patient 
management and outcomes in the ‘real-world’ which has helped to improve patient 
outcomes around the globe13-17.  
1.2.3  Management and Outcomes of ACS 
 
 
Patients with ACS present with diverse demographic and clinical characteristics 
and experience a wide range of serious cardiovascular outcomes 11, 18. Relatively limited 
multinational data are available on the post-discharge management and outcomes of ACS 
patients. The post-discharge period is a particularly critical period considering the 
proportion of ACS patients that develop adverse outcomes12, 19. Six-month case-fatality 
rates range to upwards of 7% depending on severity, comorbidities, and management12. 
Identifying patients at higher risk for unfavorable outcomes is important in guiding patient 
triage and use of effective management approaches. Studies have shown that missed 
opportunities of reperfusion together with under-prescription of effective treatments play 
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an important  role in the high post-discharge rates of unfavorable outcomes20. Targeting 
high risk populations and increasing the use of evidence based therapies is crucial to 
improving post-discharge outcomes in patients with an ACS21-24. 
Several studies examining factors associated with the receipt of evidence-based 
medications and procedures among persons with ACS/AMI have found that admission to 
teaching/academic hospitals and treatment by cardiologists are associated with higher 
utilization rates of evidence-based medications and procedures. On the other hand, being 
from a lower SES, not having medical  insurance, history of heart failure, diabetes, 
hypertension, kidney disease, PCI, or CABG, prolonged pre-hospital delay, and 
development of hospital complications were  associated with lower rates of utilization of 
evidence-based cardiac medications and interventional procedures.  
 
1.2.4 Acute Coronary Syndromes in Comparatively Young Adults 
 
Acute coronary syndromes are more common among middle aged and older 
individuals. The average age of patients with an ACS in GRACE was 65 years. Most of 
our current knowledge of the pathology underlying ACS is based on studies of patients of 
middle age or older, and some studies of patients with CHD used to exclude individuals < 
40 years old. While marked age-related differences have been observed in the risk of 
developing as well as the prognosis of ACS, few studies however examined time trends in 
the epidemiology of ACS in comparatively younger patients. This is exceedingly important 
in light of increasing trends in obesity, diabetes, and hyperlipidemia worldwide among 
young adults. In recent years, ACS has been increasingly affecting younger patients, which 
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is a matter of concern due to the resulting premature morbidity and mortality as well as the 
psychological and social burden for individuals during the most productive period of their 
lives.  
 
1.2.5 Cardiogenic Shock as a Major Complication of ACS 
  
Cardiogenic shock is the primary cause of death among patients hospitalized with 
ACS 25, 26. In spite of significant advances over the past 30 years in diagnosing cardiogenic 
shock, and in the care of patients who develop this serious complication of AMI,  
cardiogenic shock remains a devastating complication with an incidence of upwards of 8% 
among AMI patients and a 30-day mortality rate close to 50%26, 27. It is believed that 
prompt diagnosis of cardiogenic shock and rapid initiation of therapy are key factors in 
improving the prognosis of patients with this clinical complication. . Multinational 
registries offer a great tool to expand our  knowledge base with regards to identifying the 
optimal treatment strategies of cardiogenic shock patients, the extent to which early 
revascularization is adopted in the ‘real world’ as the treatment strategy of choice, and 
changes in patients’ outcomes over time28. This knowledge is necessary to inform clinical 
practice guidelines and improve patient survival29. 
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1.2.6 ACS Survey Efforts in the Gulf Countries 
 
Although developing countries will be the major contributors to the increasing 
burden of CHD, they have been poorly represented in multinational studies of CHD to 
date 30. The Arabian Gulf area (also known as the Persian Gulf) in particular and the 
Middle East in general, is a great example of developing countries that have seen limited 
CHD survey efforts. There is a considerable lack of knowledge regarding the magnitude 
and forms of CHD that exist in the Gulf area. Recent data suggest  that the prevalence of 
major CHD risk factors is on the rise among the Gulf population31. Studies have shown 
high prevalence rates of type 2 diabetes among the Gulf population reaching up to 18%32, 
33. The prevalence of obesity has also been increasing over time in several Gulf 
countries34, 35. Rates of smoking remain among the highest worldwide. For example, 34% 
of adult men in Kuwait were found to be regular smokers36, 37. Other major CHD risk 
factors are not well studied. Furthermore, little is known about ACS clinical practices in 
the Gulf area. Data from isolated studies suggest an underutilization of effective treatments 
and procedures in the Gulf area38-41. Comparing the characteristics of patients, clinical 
practice patterns of ACS, and patient outcomes in the Gulf countries to the rest of the 
world and to standard guidelines would enhance efforts of primary and secondary 
prevention in those countries. 
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1.3 Significance of Proposed Study 
 
In summary, ACS is a significant and growing public health and clinical concern. 
Despite improving trends in short-term outcomes after an ACS, important gaps between 
countries and regions as well as between individuals of different ages may persist. 
Therefore, there is a need for contemporary epidemiologic research that systematically 
describes differences in extent of patients’ characteristics, receipt of hospital treatments 
and outcomes, including mortality and complications, and to determine whether 
differences in these endpoints have changed over time. The findings of this proposed 
research will provide useful current information regarding inter-regional differences as 
well as changes over time in patient characteristics, hospital management practices, and 
hospital outcomes that can inform the design of appropriate public health interventions and 
clinical guidelines to improve the prognosis of patients with an ACS. 
1.4 Research Design and Methods 
This dissertation consists of secondary data analyses of patients enrolled in the 
GRACE and Gulf RACE project. The purpose of the proposed study was to examine 
differences in the patient characteristics, the receipt of evidence-based treatments, and in 
hospital complications and CFRs between different regions of the world as well as 
describing special subpopulations of patients with ACS including patients developing 
cardiogenic shock and patients developing ACS at a comparatively young age. A particular 
strength of this study is the use of contemporary data from two large multinational 
registries of ACS.  
11 
 
 
1.4.1 Study Designs and Patient Populations  
1.4.1.1 The Global Registry of Acute Coronary Events (GRACE) 
The GRACE study is a large, multinational, observational study of patients 
hospitalized with ACS in 14 countries in North and South America, Europe, Australia, and 
New Zealand between 1999 and 2008. The objectives of GRACE are to improve the 
hospital and long-term outcomes of patients with ACS42. 
Participating Centers and Sampling Methods 
Study hospitals were located in 18 cluster sites of 14 countries. Data collection 
activities began in April 1999 with the goal of collecting data on approximately 10,000 
patients hospitalized with ACS on an annual basis. A total of four sites were included in 
the United States (Massachusetts, Michigan, North Carolina, and California), whereas an 
additional 16 sites were included from Canada, Europe, Australia, and New Zealand. The 
two geographic clusters in South America have recruited relatively more study hospitals 
than other clusters to provide a more descriptive overview of national practices in the 
management and outcomes of patients with ACS. 
These geographic clusters were chosen to represent populations with varying 
demographic, clinical, and treatment characteristics as well as hospital systems of different 
sizes and treatment and diagnostic capabilities. A total of 46 hospitals were included at 
these population sites, representing hospitals of varying size, characteristics, and diagnostic 
and treatment capabilities. At the study clusters in which a population-based site (where 
ACS patients from geographically defined catchment areas) was considered either not 
feasible or not cost effective, a sample of hospitals representative of those from that region 
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or country was selected and cases of ACS were included irrespective of the patient’s 
geographic origin. A total of 47 hospitals were included at these study clusters. Where 
required, hospitals received approval from their local hospital’s ethics or institutional 
review board, and signed, informed consent for follow-up contact was obtained from the 
patients at enrollment. For those sites using active surveillance for case identification, 
verbal or written consent was obtained from patients to review information contained in 
their medical charts. 
Patients who died early during their index hospitalization were thereby excluded 
from study consideration at the sites where active case ascertainment was carried out. The 
impact of this and other exclusionary factors needed to be considered in interpreting 
hospital outcomes and the descriptive characteristics and treatment practices used in the 
respective study samples. 
 
Patient Identification Approaches 
To facilitate the review of medical records in a systematic manner, and 
accommodate the varying ways in which the data were collected, prospective (“warm” or 
active pursuit) and retrospective (“cold” or passive pursuit) surveillance approaches for 
identifying cases of ACS, similar to the MONICA Project23 were adopted. In hospitals that 
used warm pursuit, eligible patients were identified during the index admission and 
medical records were reviewed on an ongoing basis after appropriate consent has been 
obtained, if necessary. In study sites that used the cold pursuit method of approach to case 
identification, hospital listings of persons discharged from participating hospitals were 
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reviewed to identify potentially eligible cases with use of the International Classification of 
Diseases, Ninth Revision (ICD-9), codes 410 or 411 or corresponding codes in ICD-10. 
These charts were subsequently reviewed after the patient has been discharged from the 
hospital. The majority of study centers adopted warm pursuit whereas a limited number of 
centers used cold pursuit to identify cases of ACS. 
Patients hospitalized with a discharge diagnosis of ACS constitute the primary 
sample of interest at the clusters where passive or cold pursuit surveillance was adopted. 
At the centers where warm pursuit surveillance approaches were used, patients with an 
admission diagnosis of ACS were studied irrespective of whether their final discharge 
diagnosis is ACS, another cardiac diagnosis, or non-cardiac disease. The medical records 
of patients with a primary or secondary discharge diagnosis of AMI (ICD-9 code 410) or 
unstable angina (ICD-9 code 411) were reviewed in their entirety at the study sites using 
passive surveillance. Previous surveillance studies have shown a relatively low yield of 
confirmed cases of ACS, particularly AMI, from other possible coronary disease 
diagnostic categories (eg, ICD-9 codes 412-414, 786.5). Thus, the medical records of 
patients with a discharge diagnosis of these latter diagnostic codes were not reviewed. As 
previously mentioned, at the study sites where active or warm pursuit surveillance was 
used, hospitalized patients with a suspected diagnosis of ACS were identified on a regular 
basis and charts were concurrently reviewed. Given the varying sizes of the populations 
under study and the number of patients hospitalized with a suspected or a discharge 
diagnosis of ACS, a sampling scheme was used to select possible cases of ACS for 
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subsequent review. Each study site selected a final annual sample of approximately 600 
cases of ACS from each study cluster spread out over the entire year. 
 
GRACE inclusion/Exclusion criteria 
• Must have one of the ACS as a presumptive diagnosis. 
• Must be ≥18 years old. 
• Must be alive at the time of hospital presentation. 
• The qualifying ACS must not have been precipitated or accompanied by a significant 
comorbidity such as a motor vehicle crash, trauma, severe gastrointestinal bleeding, 
operation, or procedure. In-patients who were already hospitalized, for any reason, 
when ACS symptoms develop were not eligible for enrollment. 
• Patients transferred into or out of a registry hospital could be enrolled regardless of the 
time spent at the transferring hospital. 
• For patients transferred out of a registry hospital, data collection for the initial case 
report form ended with the transfer and indication of purpose of transfer. 
• Patients could be re-enrolled in GRACE provided that 6 months or more passed since 
the prior enrollment. When a patient was re-enrolled, a new patient number must be 
assigned. 
• The criteria for ACS must be met, with one exception: patients hospitalized for <1 day 
who died and did not meet the criteria could be enrolled provided that the cause of 
death was confirmed to be due to ACS. 
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Data Abstraction 
A standardized data abstraction form was developed for study-wide use. The team 
of investigators developed the initial case report form, which was subsequently finalized 
for field use after pilot testing at each of the participating hospitals. Information was 
collected on patient demographic characteristics, medical history, duration of pre-hospital 
delay from the time of onset of acute symptoms to seeking medical care, presenting 
symptoms, electrocardiographic findings, clinical characteristics, use of cardiac 
medications and interventional procedures, and hospital-associated outcomes. Standardized 
definitions for patient-related variables and clinical diagnoses were used. All cases of 
confirmed ACS were assigned to 1 of the following categories: ST-segment elevation 
myocardial infarction (STEMI), non–ST-segment elevation myocardial infarction 
(NSTEMI), or unstable angina (UA). Patients were diagnosed with STEMI when they had 
new or presumed new ST-segment elevation ≥1 mm seen in any location, or new left 
bundle branch block on the index or subsequent electrocardiogram with at least one 
positive cardiac biochemical marker of necrosis (including troponin measurements, 
whether qualitative or quantitative). In cases of NSTEMI, at least one positive cardiac 
biochemical marker of necrosis without new ST-segment elevation seen on the index or 
subsequent electrocardiogram had to be present. Unstable angina was diagnosed when 
serum biochemical markers indicative of myocardial necrosis in each hospital’s laboratory 
were within the normal range. Full definitions can be found on the GRACE web site 
at www.outcomes.org/grace 
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Characteristics of the GRACE Population Over Time 
Table 1.2 presents changing characteristics of the GRACE population over time. 
The mean age and sex distribution of study sample have been unchanged over time. There 
has been a lower proportion of patients presenting to GRACE hospitals with a history of 
angina, heart failure and renal disease, but a greater proportion of patients presenting with 
a history of diabetes.  The proportion of patients presenting with a history of MI and stroke 
have unchanged. In term of clinical complications and death, the proportions of patients 
developing clinical complications and dying during hospitalization have declined over time. 
Pre-hospital delay (median) has remained unchanged whereas the length of hospital stay 
has declined in the most recent study years. 
Table 1.1 Characteristics of the Global Registry of Acute Coronary Events (GRACE) 
Population Over Time 
Characteristic 1999/2001 
(n=16,951) 
2002/03 
(n=13,417) 
2004/2005 
(n=11,726) 
2006/2007 
(n=8,002) 
Age (median, yrs) 67.0 66.9 67.4 66.7 
Male (%) 66.0 66.4 66.7 67.4 
Medical history (%)     
      Angina 63.6 51.6 46.7 45.4 
      Diabetes 24.3 24.9 25.5 25.7 
      Heart failure 11.6 10.9 10.5 9.5 
      MI 31.0 30.1 30.7 31.7 
      Renal disease 8.1 7.1 8.1 7.8 
      Stroke 8.7 8.5 8.5 8.4 
Clinical complications (%)     
     Atrial fibrillation 9.1 8.4 7.2 6.4 
     Heart failure 17.2 13.7 10.7 9.3 
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1.4.1.2 The Gulf Registry of Acute Coronary Events (Gulf RACE) 
The Gulf RACE is a prospective, multinational, multicenter survey of patients 
hospitalized with an ACS in six Arabian Gulf countries - Bahrain, Kuwait, Qatar, Oman, 
United Arab Emirates (UAE) and Yemen. Gulf RACE was funded by Sanofi Aventis. The 
main goal of this registry was to study clinical practice patterns in the management of ACS 
and to assess the gap between the practice and available evidence and guidelines, and to 
then try to improve the quality of cardiac care provided to the population of the Gulf 
countries 
Study Design 
Since one of the main goals of the registry was to capture incidence rates of ACS, 
the study attempted to include the majority of consecutive ACS patients in the six 
countries involved. In Bahrain, Kuwait and Qatar, all hospitals that admit patients with 
ACS participated, while in Oman, UAE and Yemen, most hospitals (covering at least 85% 
of the population) participated. Patients were followed up for the duration of their hospital 
stay. A total of 6706 ACS patients were enrolled from 65 participating hospitals and 
     Stroke 0.9 0.7 0.7 0.5 
     Shock 4.6 3.9 3.9 3.7 
Hospital mortality (CFRs) (%) 6.0 5.7 5.0 4.6 
Median (mean) of pre-hospital 
delay, hours 
3 (76) 3 (94) 3 (24) 
3 (31) 
Mean of Length of stay, days 8.2 7.4 6.9 6.8 
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medical centers. Diagnosis of the different types of ACS and definitions of data variables 
were based on the American College of Cardiology (ACC) clinical data standards.42 
Study Population 
The Gulf RACE included all patients with a discharge diagnosis of ACS. The 
majority of patients were enrolled using warm pursuit surveillance. In addition to patients 
with an initial diagnosis of ACS, the registry also included patients who were admitted 
with different diagnoses who were then diagnosed with ACS during the hospital stay. 
There were no age limitations or other exclusion criteria. For patients to be eligible for 
enrollment, patients had to be diagnosed with MI or UA. Cases were validated through the 
review of their medical records. The Gulf RACE included both citizens and expatriates 
working in the Gulf countries. Expatriates constituted nearly 44% of the study population. 
  
Definition of MI: typical rise and gradual fall (troponin), or more rapid rise and fall 
(CK-MB) of biochemical markers of myocardial necrosis with at least one of the following: 
- Ischemic symptoms 
- Development of pathological Q waves on ECG 
- ECG changes indicative of ischemia (ST elevation or depression) 
- Coronary artery intervention 
 
Definition of UA: at least one of the following has to be present: 
- Angina that occurred at rest and was prolonged, lasting more than 20 min 
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- New-onset angina of at least Canadian Cardiovascular Society (CCS) 
classification III severity 
Recent acceleration of angina reflected by an increase in severity of at least 1 CCS 
class to at least 3 CCS class 
Data Collection and Management 
Standard case record forms (CRF) were filled out, prospectively, at the time of 
admission for each patient with suspected ACS (by whom and what quality control 
measures were employed??). The different elements of the form were filled out during the 
patients stay in the hospital until hospital discharge. For individuals whose initial 
admission was not ACS but were subsequently diagnosed with ACS, the registry form was 
filled out, retrospectively. All countries enrolled used the same CRF except for Yemen in 
which an additional question on using “Khat” (a plant that is legally consumed in Yemen 
and has an-amphetamine like stimulant effect) was added.   
CRFs were filled out by centrally trained professionals, and data were electronically 
entered into computers after being reviewed.  
Characteristics of the Gulf RACE Population  
Table 1.2 presents the characteristics of the Gulf RACE population.  
Table 1.2 Characteristics of the Gulf Registry of Acute Coronary Events (GRACE) 
Population  
Characteristic  (n=6,706) 
Age (median, yrs) 56.0 
Male (%) 76.0 
Medical history (%)  
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1.4.2 Measures and Statistical analyses 
 
1.4.2.1 Aim 1: Comparison between GRACE and Gulf RACE Patients and 
Outcomes 
Aim 1 of this proposal is to compare ACS patients in the Arabian Gulf area (Gulf 
RACE) to a sample of ACS patients from a large multinational study (GRACE) in terms of 
patient demographics, clinical characteristics, current practice patterns and in-hospital 
outcomes. The secondary objective is to compare in-hospital mortality rates between the 
two cohorts and identify factors associated with differences in mortality rates. 
 
 
      Angina 42.0 
      Diabetes 41.0 
      Hypertension 51.0 
      MI 25.0 
      Hyperlipidemia 32.0 
      Current smoking 41.0 
Clinical complications (%)  
    Cardiogenic Shock 5.0 
    Recurrent ischemia 9.0 
    Infarction 2.0 
    Stroke 0.7 
Hospital mortality (CFRs) (%) 3.8 
Mean of Length of stay, days 5.6 
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Study sample/design:  
The comparative analyses will be carried out between the complete cohort of Gulf 
RACE and the 2007 cohort of GRACE (to limit the potential confounding effect of time). 
Only in-hospital data will be used for the analyses as Gulf RACE did not include a follow-
up component.  
Measures: 
The two cohorts will be compared in terms of patient characteristics, in-hospital 
management practices, complications and outcomes. Patient characteristics will include 
demographics (eg, age, gender, BMI), past medical history (eg, angina, MI, PCI, Diabetes, 
hypertension, hyperlipidemia, smoking, family history of CAD, PCI, CABG), 
comorbidities (eg, stroke, peripheral vascular disease, kidney disease), and presentation (eg, 
cardiac arrest, heart rate, BP, Killip class, heart rhythm, STEMI, NSTEMI, UA). 
In-hospital management will include medications prescribed during hospitalization 
and on discharge (eg, ASA, heparin, Beta blockers, Glycoprotein IIb/IIIa inhibitor, calcium 
channel blocker, diuretics) in addition to procedures (eg, Catheterization, PCI, CABG, 
thrombolytics). Complications and in-hospital outcomes will include recurrent ischemia, 
infarction, mechanical ventilation, cardiogenic shock, atrial fibrillation major bleeding, 
stroke and death. 
Definitions of variables in both the GRACE protocol and the Gulf RACE protocol 
were based on the American College of Cardiology (ACC) guidelines. In examining 
factors related to differences in mortality rates between the two registries, in-hospital 
mortality is the main outcome of interest. The registry variable (GRACE or Gulf RACE) 
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will be the main independent variable. Potential confounding variables include: patient 
demographics, medical history, clinical variables, and duration of hospital stay. 
Statistical plan: 
 The GRACE and Gulf RACE data sets will be merged into one data set containing 
a variable indicating the registry to which each individual belongs. A comparison between 
GRACE and Gulf RACE in participant’s demographics, medical history, comorbidities, 
clinical presentation and length of hospital stay will first be carried out to examine 
differences and determine potential confounders that need to be accounted for in modeling 
outcomes of interest. A second comparison between the two registries will be carried out to 
examine differences in in-hospital clinical practices including prescribed medications and 
procedures. Both analyses will be age stratified to explore the interaction (effect 
modification) between age and other variables. Age categories used in comparisons will be 
decided according to the distribution of the age variable in both registries. Gender specific 
analyses will be considered if gender shows to be an effect modifier in exploratory 
analyses. To determine statistically significant differences between the two registries, the 
Chi square test will be used to compare categorical variables while Wilcoxon rank-sum test 
will be used for continuous variables. 
 To determine if differences between the two registries explain the difference in in-
hospital mortality rates, a survival analysis approach will be used. The survival analysis 
approach was chosen to account for the confounding effect of length of hospital stay 
(previous research has shown that mortality rates are related to length of hospital stay and 
23 
 
 
preliminary analyses of our data showed difference in the length of hospital stay between 
the two registries).  
Univariate analyses will be carried out to examine the potential confounders of the 
association between mortality and registry using log-rank tests. Survival curves for 
GRACE and Gulf RACE will be created using the Kaplan-Meier method. The Cox 
Proportional Hazards (PH) model will be used to examine the association of interest 
adjusting for potential confounders. A similar selection process of potential confounders 
described previously in aim 1 will be applied. Variables of the GRACE risk score will be 
forced on the model (age, HR, SBP, Creatinine, Killip class, cardiac arrest, ST- segment 
deviation and elevated cardiac enzymes). An adjusted Cox PH curve will be created to 
check the PH assumption.  
Cox PH model: log[h(t)/h0(t)] = β1,2Registry1,2+ β3-n(confounders) + βn-m(interaction 
terms) 
 
 
 
1.4.2.2 Aim 2: Outcomes of Patients with an ACS Complicated by 
Cardiogenic Shock (GRACE) 
Aim 2 of this proposal is to describe the demographic and clinical characteristics of 
patients presenting with AMI complicated by cardiogenic shock, their management, and 
outcomes. The secondary study objective is to determine factors associated with increased 
mortality among patients with ACS complicated by cardiogenic shock. Cardiogenic shock 
remains the most frequent cause of in-hospital death as a complication of ACS. 
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Study sample/design: 
Analyses will be carried out on all ACS patients in GRACE who were diagnosed 
with cardiogenic shock at admission or during hospital stay. Nearly 3,000 patients in 
GRACE were diagnosed with cardiogenic shock. Reported incidence rates range between 
5-10% and despite therapeutic advances; it continues to have devastating outcomes with 
mortality rates of over 50%.  
 
Measures: 
The primary outcome of interest in study aim 2 is mortality (hospital mortality + 6-
month mortality). Type of ACS and time of development of cardiogenic shock (at 
admission vs. during hospitalization) are the main independent variables. Potential 
confounders include:  patient demographic, medical history, clinical variables in addition 
to influence of effective cardiac medications and coronary interventional approaches. 
Operational definitions are as follows: 
Cardiogenic shock: a state of global tissue hypoperfusion due to failure of the 
cardiac ventricles to perform effectively. Cardiogenic shock is diagnosed by the criteria 
similar to Killip class IV: pulmonary edema and hypo perfusion characterized by systolic 
blood pressure < 80 mmHg. Data on Cardiogenic shock was collected during the period of 
in-hospital stay and classified according to time of diagnosis into two categories: at 
hospital presentation or during hospital stay. No data on occurrence of cardiogenic shock 
was collected in the follow-up CRFs. 
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Type of ACS: All cases of confirmed ACS were assigned to 1 of the following 
categories: ST-segment elevation myocardial infarction (STEMI), non–ST-segment 
elevation myocardial infarction (NSTEMI), or unstable angina (UA). Patients were 
diagnosed with STEMI when they had new or presumed new ST-segment elevation ≥1 mm 
seen in any location, or new left bundle branch block on the index or subsequent 
electrocardiogram with at least one positive cardiac biochemical marker of necrosis 
(including troponin measurements, whether qualitative or quantitative). In cases of 
NSTEMI, at least one positive cardiac biochemical marker of necrosis without new ST-
segment elevation seen on the index or subsequent electrocardiogram had to be present. 
Unstable angina was diagnosed when serum biochemical markers indicative of myocardial 
necrosis in each hospital’s laboratory were within the normal range. 
Mortality:  during the index hospitalization. Exact date of death was recorded in 
addition to the main cause of death.  
Definitions of other in-hospital adverse outcomes followed the ACC definitions of 
key variables. 
.  
Statistical plan: 
For, all statistical plans, examination of the distributions of all dependent and 
independent variables will be carried out to determine the appropriateness of model 
distributional assumptions for dependent variables (outcomes) and variability of 
independent variables (predictors). The distribution of the predictors will help assess the 
informational content and inform the process of variable categorization if needed. 
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Descriptive and graphical analyses of the characteristics of hospital survivors, as compared 
to decedents, among ACS patients stratified by type of ACS will be carried out. 
Differences in the distribution of patient characteristics between the primary comparison 
groups (STEAMI, NSTEAMI, and UA) will be examined using chi-square tests of 
statistical significance for categorical variables and the Kruskal-Wallis test for continuous 
variables. Functional associations between different variables will be examined as well as 
between covariates and the outcome of interest (assumptions of linearity will be checked 
for continuous and ordinal variables). Assumptions of proportional hazards will be 
checked for Cox proportional hazards models. 
First, an analysis of differences in the distribution of patient characteristics between 
ACS patients with cardiogenic shock vs. ACS patients who did not develop cardiogenic 
shock during their index hospitalization will be carried out. A repeat of the previous 
analysis will be carried out stratified by type of ACS (STEMI, NSTEMI, and UA). 
Differences between groups will be examined using chi-square tests of statistical 
significance for categorical variables and the Kruskal-Wallis test for continuous variables. 
Second, an analysis will be carried out to compare the characteristics of cardiogenic shock 
patients enrolled in the last 2 years of GRACE to those enrolled over the complete study 
period will be carried out to determine if any changes in the characteristics of patients or 
their presentation has taken place over the 9 year period of the study. Third, similar 
analyses will be carried out to describe the clinical management including medications and 
procedures used for cardiogenic shock patients stratified by type of ACS and by time of 
diagnosis of cardiogenic shock (at admission vs. during hospitalization) will be performed.  
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Two approaches will be used to examine the association between mortality and 
type of ACS as well as between mortality and time of development of cardiogenic shock 
(at presentation vs. during hospitalization). The first will be a logistic regression while the 
second will be a Cox-proportional hazards approach. In each approach, univariate analyses 
will be carried out to examine potential confounders (eg. demographic, medical history, 
clinical variables and others) of the association between the outcomes of interest and types 
of ACS. Variables with p values <0.1 will be considered for inclusion in the multivariable 
models.  
In the multivariable models, CS will be forced into the models first and then 
potential confounding variables selected from the univariate analyses will be added one by 
one in a forward selection fashion. Potential confounders will be included in the models if 
they are statistically significant (p<0.05) or change the point estimates of ACS type 
variable by at least 10%. Variables that fail to pass the screening in the univariate analyses 
will be re-considered in the final models.  
To examine whether the association between CS and outcomes of interest has 
changed over time, an interaction term between CS and study year will be included in the 
models previously built. Likelihood ratio tests comparing models with and without 
interaction terms will be used to examine whether the interaction terms are statistically 
significant. 
Logistic model: logit(E(Y|x))= β0+β1,2CS1,2 + β4-n(confounders) )+ βn-minteraction 
terms 
For the first approach, model fitting will be examined using Hosmer-Lemeshow 
Goodness of fit test for logistic regression. 
28 
 
 
For the second approach, a life-table will be used to examine differences in 6 
outcomes between types of patients with and without CS including patients with varying 
lengths of follow-up. The reported outcomes rates will be calculated from these life-table 
analyses. Incidence rates of outcomes of interest over the study period will be analyzed. A 
proportional hazards regression approach will be used to examine differences between the 
comparison groups with regard to outcomes of interest while controlling for potentially 
confounding demographic, medical history, and clinical variables. Similar univariate 
analyses followed by multivariable regression modeling as described previously for 
logistic regression will be applied. Univariate analyses will be carried out to examine the 
potential confounders of this association using log-rank tests and survival curves be 
created using the Kaplan-Meier method. A similar selection process of potential 
confounders described previously for logistic regression will be applied. Time dependent 
variables will be included if needed. An adjusted Cox proportional hazards curve will be 
created. In examining whether associations of interest have changed over time, similar 
approaches described for logistic regression will be used. 
 
Cox PH model: log[h(t)/h0(t)] = β0,1CS0,1+ β4-n(confounders)+ βn-minteraction terms 
 
Separate regression analyses (separate models for each type of ACS: STEMI, 
NSTEMI and UA) will be performed to examine baseline demographics, medical history, 
and clinical factors associated with occurrence of death in patients with STEMI, NSTEMI, 
and unstable UA. Goodness of fit of our final models will be assessed and C statistics will 
be examined. 
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1.4.2.3 Aim 3: Acute coronary syndromes in comparatively young adults 
(≤55 years) 
Aim 3 of the study is to examine trends in frequency rates, patient 
characteristics, hospital treatment practices, and short-term outcomes in 
comparatively young adults (<55 years old) who had been hospitalized with an 
ACS.  
Study sample/design: 
Analyses will be carried out on all ACS patients in GRACE who were ≤55 years. 
Nearly 15,000 patients in GRACE were enrolled in GRACE between 1999 and 2007 and 
were ≤55 years of age, representing around 23% of the total study population.  
 
Measures: 
The outcomes of interest in study aim 3 are patients characteristics, treatments, 
adverse outcomes, and mortality (hospital mortality + 30-day mortality). The study period 
(3 categories) is the main independent variable. Potential confounders include:  patient 
demographic, medical history, clinical variables in addition to influence of effective 
cardiac medications and coronary interventional approaches. 
Operational definitions are as follows: 
Young patients: the cutoff age used to define young patients in previously 
published literature on ACS patients has been 10 years less than the average age. Since the 
30 
 
 
average age of patients enrolled in GRACE is 65 years, we chose the age of 55 years as the 
cutoff point to identify young patients.  
Time periods: the GRACE study period extending between 1999 and 2007 (a total 
period of 9 years) will be divided into three equal time periods, 1999 to 2001, 2002 to 2004, 
and 2005 to 2007. The three time periods will be used to examine near decade time trends, 
and as a mean to simplify the presentation of the results.   
Type of ACS: All cases of confirmed ACS were assigned to 1 of the following 
categories: ST-segment elevation myocardial infarction (STEMI), non–ST-segment 
elevation myocardial infarction (NSTEMI), or unstable angina (UA). Patients were 
diagnosed with STEMI when they had new or presumed new ST-segment elevation ≥1 mm 
seen in any location, or new left bundle branch block on the index or subsequent 
electrocardiogram with at least one positive cardiac biochemical marker of necrosis 
(including troponin measurements, whether qualitative or quantitative). In cases of 
NSTEMI, at least one positive cardiac biochemical marker of necrosis without new ST-
segment elevation seen on the index or subsequent electrocardiogram had to be present. 
Unstable angina was diagnosed when serum biochemical markers indicative of myocardial 
necrosis in each hospital’s laboratory were within the normal range. 
Mortality:   in-hospital and death during the 30 days following admission. Exact 
date of death was recorded in addition to the main cause of death.  
Definitions of other in-hospital adverse outcomes followed the ACC definitions f 
key variables. 
 
31 
 
 
Statistical plan: 
For, all statistical plans, examination of the distributions of all dependent and 
independent variables will be carried out to determine the appropriateness of model 
distributional assumptions for dependent variables (outcomes) and variability of 
independent variables (predictors). The distribution of the predictors will help assess the 
informational content and inform the process of variable categorization if needed. 
Descriptive and graphical analyses of the characteristics patients, treatments received, in-
hospital outcomes, and mortality will be compared according to the study period they fall 
under. Differences in the distribution of patient characteristics between the primary 
comparison groups will be examined using chi-square tests of statistical significance for 
categorical variables and the Kruskal-Wallis test for continuous variables. Functional 
associations between different variables will be examined as well as between covariates 
and the outcome of interest (assumptions of linearity will be checked for continuous and 
ordinal variables). Assumptions of statistical models will be checked. 
Chi-square tests for categorical variables and ANOVA for continuous variables 
will be used to examine potentially changing trends in various demographic and clinical 
factors. The short-term outcomes in each period will be examined by calculating in-
hospital and 30-day case-fatality rates and trends in these endpoints will be examined 
through the use of chi-square tests for trends. Logistic regression modeling will be used to 
assess the significance of a near decade trends in short-term death rates while controlling 
for several potentially confounding demographic, medical history, and clinical 
characteristics of prognostic importance.   
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For purpose of building the logistic regression model, univariate analyses will be 
carried out to examine potential confounders (eg. demographic, medical history, clinical 
variables and others) of the association between the outcomes of interest and the study 
period. Variables with p values <0.1 will be considered for inclusion in the multivariable 
models.  
In the multivariable models, the study period will be forced into the models first 
and then potential confounding variables selected from the univariate analyses will be 
added one by one in a forward selection fashion. Potential confounders will be included in 
the models if they are statistically significant (p<0.05) or change the point estimates of 
ACS type variable by at least 10%. Variables that fail to pass the screening in the 
univariate analyses will be re-considered in the final models.  
Logistic model: logit(E(Y|x))= β0+β1,2CS1,2 + β4-n(confounders) )+ βn-minteraction 
terms 
Model fitting will be examined using Hosmer-Lemeshow Goodness of fit test for 
logistic regression. 
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Abstract 
 
The Arab Middle East is a unique region of the developing world where little is known 
about the outcomes of patients hospitalized with an acute coronary syndrome (ACS), 
despite playing an important role in the global burden of cardiovascular disease. The 
primary objectives of this observational study were to compare patients with ACS 
hospitalized in the Arab Middle East to patients enrolled in a multinational non-Arabian 
ACS registry. The study cohort consisted of patients hospitalized in 2007 with an ACS, 
including 4,445 from the Global Registry of Acute Coronary Events (GRACE) and 6,706 
from the Gulf Registry of Acute Coronary Events (Gulf RACE). The average age of 
patients in Gulf RACE was nearly a decade younger than GRACE (56 vs 66 years). 
Patients in Gulf RACE were more likely to be male, smoke, and diabetic, while they were 
less likely to be hypertensive compared with GRACE patients. Patients in Gulf RACE had 
a higher odds of receiving aspirin, and lower likelihood of receiving ACE inhibitors/ARBs, 
β-blockers and clopidogrel during their index hospitalization. While the majority of 
eligible patients with ST- elevation myocardial infarction in Gulf RACE received 
thrombolytics, the majority of their counterparts in GRACE underwent a primary PCI. 
Multivariable adjusted in-hospital case-fatality rates were not significantly different 
between Gulf RACE and GRACE patients. In conclusion, despite differences in patient 
characteristics and treatment practices, short-term mortality rates were comparable 
between ACS patients enrolled in these two registries.  Future studies should explore the 
effects of these differences on long-term prognosis and other pertinent patient outcomes. 
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2.1  Introduction 
 
The primary objectives of this observational study were to compare the characteristics, 
management, and short-term outcomes of patients hospitalized with an acute coronary 
syndrome (ACS) in the Arab Middle East with a large multinational sample of patients 
with ACS using patient level data from two large ACS registries.1,2 
2.2 Methods 
Full details of the Global Registry of Acute Coronary Events (GRACE) and Gulf 
Registry of Acute Coronary Events (Gulf RACE) projects have been previously 
published.1-4  
 
Gulf RACE is a prospective registry of all patients hospitalized with an ACS in 65 
centers in 6 Arab Middle Eastern countries (Kuwait, Oman, United Arab Emirates, Yemen, 
Qatar, and Bahrain). Patients were enrolled in this observational study from January to 
June, 2007. All hospitals that care for patients with ACS in Kuwait, Bahrain, and Qatar 
participated, as did the majority of hospitals in Yemen, United Arab Emirates, and 
Oman2,4.  
 
GRACE is the largest multinational prospective registry designed to reflect an 
unselected population of patients hospitalized with an ACS. A total of 123 hospitals 
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located in 14 countries in North and South America, Europe, Australia, and New Zealand 
have contributed data to this registry between 1999 and 2007. For purposes of the present 
analyses, we used contemporaneous individual patient data of ACS patients enrolled in 
both registries during calendar year 2007.1,3  
 
All patients with a clinical history of ACS accompanied by at least one of the following 
were included in the respective study samples: electrocardiographic (ECG) changes 
consistent with ACS, serial increases in cardiac biomarkers of necrosis, or documented 
coronary artery disease. Patients were diagnosed with ST-elevation myocardial infarction 
(STEMI), non ST- elevation myocardial infarction (NSTEMI) or unstable angina (UA) 
using standardized criteria based on clinical presentation, ECG findings, and cardiac 
biomarkers.5,6  In both patient registries, the diagnosis of ACS and definitions of key study 
variables and clinical complications were similar and were based on the American College 
of Cardiology key data elements.7 Information about the use of coronary artery bypass 
surgery (CABG) was not collected in Gulf RACE.  
For ease of interpretation, patients with an STEMI and patients with left bundle branch 
block (LBBB) were considered as one category (STEMI) while NSTEMI and UA patients 
were combined into a single category (NSTE-ACS). 
 
Univariate comparisons of patient characteristics, clinical presentation, management 
practices, and outcome data were carried out using Wilcoxon rank sum or χ2 tests. Short-
term hospital survival rates were estimated using the Kaplan-Meier method. Cox 
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proportional hazards models were employed to compare the hazards of in-hospital death 
between patients enrolled in the two registries while controlling for potentially 
confounding variables of prognostic importance. Two multivariable adjusted models were 
built; in the first, we adjusted for age and sex only, while in the second we additionally 
controlled for all baseline characteristics and clinical presentation variables that were 
significantly associated with in-hospital mortality in the univariate analyses. Logistic 
regression modeling was used to more systematically examine differences in the risk of 
adverse in-hospital outcomes, other than death, between patients enrolled in the two 
registries while controlling for potential confounding demographic and clinical 
characteristics. We did not control for the use of hospital treatments due to the non-
randomized nature of this study and potential for confounding by indication.  
2.3 Results  
 
A total of 11,151 patients (4,445 from GRACE and 6,706 from Gulf RACE) with a 
confirmed diagnosis of ACS admitted in 2007 comprised our study population. Of the 
patients in Gulf RACE, 39% had an STEMI; of the patients enrolled in GRACE, 34% 
developed an STEMI. 
 
Patients in Gulf RACE were, on average, nearly a decade younger than patients 
enrolled in GRACE. The proportion of patients less than 55 years old in Gulf RACE was 
approximately twice that in GRACE while the proportion of patients 75 years and older  in 
Gulf RACE was less than one third that of GRACE (Table 1).  
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Patients in Gulf RACE were more likely to be male, diabetic, currently smoke, and 
have renal impairment than patients enrolled in GRACE; on the other hand, these patients 
were less likely to be hypertensive or have previously undergone coronary 
revascularization. These differences remained when we examined the distribution of these 
characteristics between the two registry populations according to ACS type (Table 1). 
 
Patients developing an STEMI in Gulf RACE were more likely to experience 
longer pre-hospital delays in seeking medical care compared to patients included in 
GRACE. Among  2,540 patients with STEMI in Gulf RACE who presented within 24 
hours of acute symptom onset, 784 (31%) presented >12 hours after symptom onset;  in 
GRACE, 1,381 STEMI patients presented within 24 hours of symptom onset , of which 
139 (10%) presented >12 hours after acute symptom onset. The average hospital stay was 
significantly shorter for ACS patients included in Gulf RACE by nearly one day (Table 1). 
 
In terms of clinical presentation, patients in Gulf RACE were more likely to present 
with higher heart rate and initial glucose values, and in a higher Killip class, compared to 
patients enrolled in GRACE. These differences persisted when comparing the respective 
study populations across type of ACS (Table 2).  
 
While Gulf RACE patients were more likely to have been prescribed aspirin, 
nitrates, and statins, they were less likely to have received β-blockers, angiotensin-
converting enzyme (ACE) inhibitors / angiotensin receptor blockers (ARB), calcium 
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channel blockers, clopidogrel, or glycoprotein IIb/IIIa antagonists compared to patients 
enrolled in GRACE during the first 24 hours of hospital admission. Gulf RACE patients 
were more likely to have been managed with intravenous heparin compared to patients 
enrolled in GRACE, who were more likely to have been managed with low molecular 
weight heparin. Similar patterns were observed when comparing patients with an STEMI 
between the two registries (Figures 1.A. and 1.B.). Nearly 75% of GRACE hospitals had 
on-site catheterization facilities compared with only 20% of Gulf RACE hospitals. In 
addition, nearly all hospitals in GRACE had coronary care units compared to less than 65% 
of hospitals in Gulf RACE.  
 
 Cardiac catheterization was performed nearly 4 times as frequently in GRACE 
compared to Gulf RACE in both STEMI patients (81.1%vs.18.0%), and in NSTE-ACS 
patients (59.4% vs 13.1%).Thrombolysis was the reperfusion strategy of choice among 
STEMI patients enrolled in Gulf RACE compared to GRACE. Patients who developed an 
STEMI in GRACE were more likely to receive primary percutaneous coronary 
intervention (PCI). A total of 1,242 patients with STEMI in GRACE presented within 12 
hours of symptom onset, of whom 163 (13%) received thrombolytics, 805 (65%) received 
primary PCI, 13 (1%) underwent CABG, and 261 (21%) did not receive any reperfusion 
modality. In Gulf RACE, 1,756 patients with STEMI presented within 12 hours of 
symptom onset, of whom 1,364 (78%) received thrombolytics, 227 (13%) received 
primary PCI, and 165 (9%) did not receive any form of coronary reperfusion therapy 
(Figure 2). 
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While patients in Gulf RACE, irrespective of their ACS diagnosis, were at higher 
risk for developing heart failure during their index hospitalization, only STEMI patients in 
Gulf RACE had a significantly higher risk of developing cardiogenic shock compared to 
patients included in GRACE. On the other hand, patients in Gulf RACE had a significantly 
lower risk of developing major bleeding during their hospitalization (Table 3).  Gulf 
RACE patients experienced higher in-hospital case-fatality rates (CFR)compared with 
GRACE patients (1.3% vs 1.9%; 1.9% vs 3.5%; 3.7% vs 5.4%; and 7.7% vs 10.8%) in 
each of the  age strata examined (<55, 55-64, 65-74, and  ≥75 years) respectively (all p 
values ≤ 0.05 except for the <55 years group) . 
 
  Using survival modeling to account for differences in hospital length of stay, and  
controlling for age and sex, Gulf RACE patients had  a higher  risk of dying in-hospital 
(HR=1.41, CI= 1.23, 1.67). After controlling for additional characteristics of prognostic 
importance, there were no statistically significant differences in the risk of dying in-
hospital between patients enrolled in the two registries (Table 3). 
 
Multivariable adjusted odds ratios (OR) showed that Gulf RACE patients were at 
significantly greater risk for developing heart failure, cardiogenic shock, and stroke, while 
being at lower risk for developing major bleeding during their index hospitalization (Table 
3).  
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2.4 Discussion and Conclusions 
 
The present study is the first to compare the characteristics, management practices, 
and hospital outcomes of patients with ACS in the Arab Middle East to a large 
multinational and predominantly “Western” population hospitalized with ACS.  Our study 
shows that ACS patients in the Arab Middle East were younger, more likely to have 
diabetes, and currently smoke cigarettes. They were more likely to present to participating 
hospitals after prolonged delay after the onset of acute coronary symptoms and were less 
likely to receive evidence-based cardiac therapies. Patients with ACS in the Arab Middle 
East had comparable in-hospital death rates to their counterparts in GRACE but had higher 
rates of in-hospital clinical complications.   
 
Prior work has suggested that patients with ACS in the Gulf region are more likely 
to develop ACS at an earlier age and have a higher prevalence of diabetes and smoking2,8,9; 
similar findings were observed in the present study. The average age of patients in Gulf 
RACE was nearly a decade younger than that of patients enrolled in GRACE.  This 
striking difference might have resulted from differences in the coronary risk factor profile 
between the two cohorts leading to earlier development of ACS or acceleration of 
underlying coronary atherosclerosis among subjects in the Arab Middle East. The 
markedly high prevalence of diabetes observed among Gulf RACE patients, despite their 
younger age, may partially reflect shifts in diet and lifestyle practices towards a more 
westernized one.10  Similarly, the high cigarette smoking rates reported in Gulf RACE 
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likely reflect the late adoption of smoking awareness campaigns and the lack of public 
smoking bans in most Gulf countries.  
 
More than 30% of patients with STEMI in Gulf RACE presented after 12 hours of 
acute symptom onset compared to 10% of those enrolled in GRACE. Prolonged delays in 
seeking acute medical care have been associated with the sub-optimal initiation of 
evidence-based management strategies and unfavorable hospital outcomes.11  Future 
studies should explore the factors and reasons associated with late hospital presentation 
among ACS patients residing in the Gulf region.  
Patients in Gulf RACE were more likely to present to participating hospitals with 
an STEMI and in a higher Killip class, suggesting a more severe form of the disease or late 
presentation compared to patients enrolled in GRACE. The risk profile of patients 
hospitalized with an ACS in the Arab Middle East and their late presentation seems to 
place them at higher odds for unfavorable cardiac outcomes despite their younger age.  
 
Regional variations in ACS management practices throughout the world have been 
previously reported12-14 and have been partially explained by differences in health care 
models and rapidity of adopting evidence-based medicine guidelines. The observed 
differences in the types of hospitals and their facilities between the two registries might 
have affected the clinical management strategies used. 
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There were fundamental differences between the two patient registries in the use of 
interventional cardiology procedures as well as medical treatments; these differences were 
particularly noted in STEMI patients in need of urgent intervention. Despite differences in 
reperfusion modalities, the overall reperfusion rate in eligible STEMI patients was higher 
in Gulf RACE compared to GRACE (91% vs. 78%, respectively), and the reperfusion 
shortfall rate observed in Gulf RACE (9%) was lower than what has been previously 
reported from other ACS registries15,16. These differences appear to be driven by local 
practice and availability of services and trained interventionalists rather than by patient 
characteristics or perceived risk. Similar inter-regional differences have been reported by 
previous studies showing that physicians in the U.S. and Europe adopted more aggressive 
coronary reperfusion strategies earlier than the rest of the world.14,17,18 
 
 While patients in Gulf RACE were at higher odds for receiving aspirin, nitrates, 
and statins, they were less likely to receive other cardiac medications associated with better 
outcomes. These differences could have resulted from the striking differences in the use of 
cardiac catheterization and reperfusion modalities between the two cohorts. They could 
also be related to different clinical practices, insurance systems, and types of hospitals 
included.  
 
Regional as well as inter-country differences in the short-term clinical outcomes of 
patients hospitalized with an ACS have been previously observed.13,14,19,20  Patients in Gulf 
RACE were more likely to have developed heart failure and cardiogenic shock during their 
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index hospitalization than patients enrolled in GRACE. This could be due to differences in 
hospital management strategies between the respective patient populations, including the 
use of invasive procedures as evidenced by a higher risk of major bleeding episodes for 
GRACE patients. In addition, it is possible that other unaccounted for factors could have 
led to the observed differences in these clinical outcomes. 
 
Despite the younger age of Gulf RACE patients, there was no significant difference in 
crude in-hospital CFRs between the two study cohorts. Comparison of in-hospital CFRs 
between the two cohorts, adjusted for age and sex differences, suggested a higher risk of 
dying during hospitalization for Gulf RACE compared to GRACE patients. Multivariable 
analyses further adjusted for differences in baseline characteristics and clinical presentation 
revealed no short-term survival advantage for one cohort over the other despite significant 
differences in treatment strategies between the 2 registries. The higher risk of dying for 
Gulf RACE patients compared to their counterparts from GRACE of a similar age and sex 
might be partially explained by the higher rates of coronary disease risk factors and more 
prolonged delays in seeking medical care. Higher primary PCI/thrombolysis ratio and 
greater use of evidence-based medications for GRACE patients did not translate into a 
short-term survival advantage. The very low reperfusion shortfall rate for eligible patients 
in Gulf RACE might partially explain the observed lack of differences in short-term 
mortality rates. On the other hand, GRACE patients had a lower risk of important short-
term complications including heart failure, cardiogenic shock, and stroke. Potential 
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explanations for the higher rates of short-term complications in Gulf RACE include 
differences in the receipt of different treatment modalities and more prolonged delays in 
seeking medical care.21 
 
Similar findings to our study were observed in a meta-analysis based on data from the 
Gulf region which found that the majority of patients with an STEMI were managed by 
thrombolytics and had favorable outcomes.22 A study comparing patients enrolled in the 
U.S. to their Canadian counterparts in the GUSTO-I trial reported that, despite the higher 
utilization of invasive cardiac procedures in the U.S., favorable outcomes were only 
observed when comparing long-term mortality rates while short-term mortality rates were 
comparable.23,24 
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Table 2.1 Baseline Characteristics of Patients hospitalized with an Acute Coronary Syndrome (ACS) 
 
Characteristic  All ACS  STEMI  NSTE-ACS  
GRACE 
07 
4,445 
Gulf 
RACE 
6,706 
P-
value 
GRACE 
07 
1,504(34%) 
Gulf 
RACE 
2,619(39%) 
P-
value 
GRACE 
07 
2,941(66%) 
Gulf 
RACE 
4,087(61%) 
P-
value 
Age (Years), 
mean (SD)  
65.5(13)  56.4(13)  <0.01 63.8(14)  54.4(13)  <0.01 67.3(13)  57.3(13)  <.01 
Age (Years)          
      <55 1,039(23%)       3,099(46%)  428(28%)       1,399(53%)  611(21%)       1,700(42%)  
      55 - 64 1,136(26%)       1,830(27%)  389(26%)         656(25%)  747(25%)       1,174(29%)  
     65 - 74 1,061(24%)       1,232(18%)  331(22%)
  
395(15%)  730(25%)         837(21%)  
     ≥75 1,209(27%)         545(8%) <0.01 356(24%)         169(7%) <0.01 853(29%)         376(9%) <0.01 
Male  3,072(69%) 5,071(76%) <0.01 1,099(73%) 2,250(86%) <0.01 1,973(67%) 2,821(69%) 0.08 
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BMI, 
Mean(SD) 
28.1(5.7) 27.6(5.4) <0.01 27.5(5.0) 26.8(4.8) <0.01 28.4(6.0) 28.1(5.6) 0.030 
    Diabetes 
Mellitus  
1,181(27%) 2,745(41%) <0.01 328(22%) 841(32%) <0.01 853(29%) 1,904(47%) <0.01 
   
Hypertension  
2,929(66%) 3,364(50%) <0.01 851(57%) 890(34%) <0.01 2,078(71%) 2,474(61%) <0.01 
   Prior PCI or 
CABG  
1,227(28%) 1,049(16%) <0.01 217(15%) 173(7%) <0.01 1,010(35%) 876(22%) <0.01 
   Current 
smoker  
1,217(28%) 2,452(37%) <0.01 536(36%) 1,318(50%) <0.01 681(23%) 1,134(28%) <0.01 
   Renal 
Impairment  
691 (16%) 1,170(18%) 0.01 188(13%) 459(18%) <0.01 503(17%) 711(18%) 0.40 
Length of 
Stay(mean,  
days)  
6.6(6.8) 5.6(4.6) <0.01 6.6(6.9) 6.1(4.3) <0.01 6.6(6.8) 5.2(4.7) <0.01 
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Table 2.2 Clinical Presentation of Patients Hospitalized with an Acute Coronary Syndrome (ACS) 
Characteristic  All ACS  
P-
value 
STEMI  
P-
value 
NSTE-ACS  
P-
value GRACE 
07 
4,445 
Gulf 
RACE 
6,706 
GRACE 
07 
1,504(34) 
Gulf 
RACE 
2,619(39) 
GRACE 
07 
2,941(66) 
Gulf 
RACE 
4,087(61) 
Heart Rate , mean(SD) (bpm) 79.0(21) 86.0(23) <0.01 79.0(22) 85.1(23) <0.01 79.0(21) 87.0(23) <0.01 
Systolic BP , mean(SD) (mm 
Hg)  
140.0(29) 140.0(31) 0.70 136.0(30) 134.0(31) 0.30 142.0(29) 143.0(30) 0.30 
Initial Glucose, mean(SD) 
(mg/dl)  
158.0(267) 196.0(193) <0.01 168.0(155) 200.0(154) <0.01 153(310) 193(214) <0.01 
Initial Creatinine, mean(SD) 
(mg/dl)  
1.21(0.9) 1.22(1.1) 0.50 1.17(0.8) 1.2(0.9) 0.30 1.24(0.9) 1.24(1.2) 0.80 
Killip Class  
     I  3756(85%) 5219(78%) <0.01 1251(83%) 2068(79%) <0.01 2505(85%) 3151(77%) <0.01 
     II  416 (9%) 874(13%) <0.01 152(10%) 322(12%) 0.030 264(9%) 552(14%) <0.01 
     III  167 (3.8%) 460(6.9%) <0.01 56(3.8%) 139(5.3%) 0.020 111(3.8%) 321(7.9%) <0.01 
     IV  46(1.1%) 137(2.1%) <0.01 24(1.6%) 86(3.3%) <0.01 22(0.8%) 51(1.3%) 0.040 
Cardiac Arrest  161(3.7%) 168(2.5%) <0.01 75(5.0%) 125(4.8%) 0.70 86(3.0%) 43(1.1%) <0.01 
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Table 2.3 In-hospital Complications of Patients Hospitalized with an Acute Coronary syndrome (ACS) 
 
In-hospital 
Outcome 
All ACS  STEMI  NSTE-ACS  
GRACE0
7 
4,445 
Gulf 
6,706 
P-
valu
e 
Adjusted OR 
(CI) 
GRACE0
7 
1,504(34) 
Gulf 
2,619(39) 
P-
valu
e 
Adjusted OR 
(CI) 
GRACE0
7 
2,941(66) 
Gulf 
4,087(61) 
P-
valu
e 
Adjusted OR 
(CI) 
Cardiogenic 
Shock  
142(3.2%) 347(5.2%) <0.0
1 
1.39(1.06,1.83
) 
83(5.5%) 252(9.6%) <0.0
1 
1.69(1.42,1.93
) 
59(2.0%) 95(2.3%) 0.37 1.26(1.09,1.48) 
Heart Failure  384(9%) 1,099(16%
) 
<0.0
1 
2.23(1.91,2.56
) 
177(12%) 454(17%) <0.0
1 
1.92(1.54,2.39
) 
207(7%) 645(16%) <0.0
1 
2.81(2.33,3.39) 
Echocardiograph
y Done 
2,634(60%
) 
4,146(62%
) 
0.03  1,098(74%
) 
1,845(71%
) 
0.04  1,536(53%
) 
2,301(56%5
) 
<0.0
1 
 
LVEF≤40% 709(16%) 1,283(19%
) 
<0.0
1 
 322(21%) 620(24%) <0.0
1 
 387(13%) 663(16%) <0.0
1 
 
Major Bleeding  89(2.0%) 52(0.8%) <0.0
1 
0.37(0.25,0.54
) 
36(2.4%) 31(1.2%) <0.0
1 
0.49(0.30,0.81
) 
53(1.8%) 21(0.5%) <0.0
1 
0.27,(0.16,0.44
) 
Stroke  21(0.5%) 49(0.7%) 0.09 2.45(1.25,4.82
) 
9(0.6%) 32(1.2%) 0.05
4 
3.32(1.28,8.63
) 
12(0.4%) 17(0.4%) 0.96 1.59(0.66,3.83) 
Death  167(3.8%) 247(3.7%) 0.84 1.09(0.84,1.41
) 
93(6.2%) 172(6.6%) 0.63 1.29(0.92,1.79
) 
74(2.5%) 75(1.8%) 0.06 0.77(0.53,1.13) 
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Figure 2.1.A Use of in-hospital Medications (first 24 hours) in All Patients with an 
Acute Coronary Syndrome (ACS) 
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Figure 2.1.B Use of in-hospital Medications (first 24 hours) in Patients with an ST-
elevation Myocardial Infarction
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Figure 2.2 Receipt of Reperfusion Therapy in Eligible Patients with ST-elevation 
Myocardial Infarction 
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Abstract 
Introduction 
 Cardiogenic shock (CS) is the leading cause of death for patients with an acute coronary 
syndrome (ACS). Despite impressive advances in the management of ACS, the frequency 
of cardiogenic shock among patients hospitalized with an ACS has remained relatively 
constant over the past several decades, and mortality remains unduly high in these high 
risk patients. 
Objectives 
 To describe the characteristics, clinical management, and hospital outcomes of patients 
with an ACS complicated by CS. Our secondary objective was to describe decade long 
trends in the incidence and hospital case-fatality rates (CFRs) of CS, and predictors of 
increased hospital mortality in these patients.  
Methods 
 The study sample consisted of all patients enrolled in the Global Registry of Acute 
Coronary Events (GRACE) between 1999 and 2007 with a confirmed ACS.   
Results 
 Of all patients with ACS enrolled in GRACE, 2,992 (4.6%) developed CS. Compared to 
patients who did not develop CS, patients with CS were more likely to be older (mean 
age 71 vs. 65 years), female, have a history of diabetes, and heart failure, and present 
with ST-segment elevation. Cardiac catheterization was performed on 1,706 (57%) and 
in-hospital revascularization on 1,408(47%) patients with CS. Patients with CS were less 
likely to receive effective adjunctive cardiac medications as ACE inhibitors, aspirin and 
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β-blockers compared to patients who did not develop CS. The in-hospital CFR of patients 
with CS was 59.4% compared to 2.3% in those who did not develop CS. Hospital CFR 
was lower for patients who underwent revascularization compared with those in whom a 
conservative medical approach was adopted (45% vs. 72%). Factors associated with an 
increased risk of in-hospital death in CS patients included advanced age, history of 
diabetes mellitus, heart failure, renal insufficiency. Adjusted incidence rates of CS 
showed slight declines over the study period (OR= 0.97 per year, CI= 0.95 - 0.98) as well 
as in hospital CFRs (OR= 0.94 per year, CI= 0.90 - 0.99), while In-hospital 
revascularization rates increased (OR= 1.09 per year, CI= 1.06 - 1.12).   
Conclusion 
 Despite the increasing use of evidence-based therapies, the overall hospital CFR of CS 
remains high (59%) and incidence showed only slight declines between 1999 and 2007. 
 
Key words: Acute coronary syndrome, cardiogenic shock & outcomes 
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3.1 Introduction 
 
Cardiogenic shock (CS) remains the most serious complication and the leading 
cause of death for patients hospitalized with an acute coronary syndrome1, 2 (ACS). 
Although cardiogenic shock is more commonly encountered with ST-elevation 
myocardial infarction (STEMI), it may also develop in patients with a non ST-elevation 
acute coronary syndrome (NSTE-ACS).   
Despite recent studies suggesting possible declines in the risk of dying during 
hospitalization for patients with CS, which has been linked to advances in medical 
treatment, revascularization techniques, and mechanical support, in-hospital case-fatality 
rates associated with CS remain high  exceeding 50% (55%-80%)3. Moreover, despite the 
clinical importance of this serious clinical complication, the incidence rates of CS in 
patients with an ACS have remained relatively constant over the past 30 years averaging 
approximately 7% (5%-10%).3-5 Utilizing data from a large multinational coronary 
disease registry, we describe the demographic and clinical characteristics of patients 
presenting with an ACS complicated by CS, the management of these high risk patients, 
and their short-term outcomes compared with patients who did not develop CS.  A  
secondary study objective was to describe nearly decade long (1999-2007) trends in the 
incidence and case-fatality rates of CS complicating ACS and factors associated with an 
increased risk of dying in patients with CS.  
 
59 
 
 
3.2  Methods 
 
 
The full details of the methods used in the Global Registry of Acute Coronary 
Events (GRACE) study have been previously published6. 
This multinational prospective study was designed to reflect an unselected 
population of patients with an ACS, irrespective of geographic region. A total of 123 
hospitals located in 14 countries in North and South America, Europe, Australia, and 
New Zealand have contributed data to this study. Adult patients (18 years of age) 
admitted with a presumptive diagnosis of ACS were potentially eligible. Patients with 
non-cardiovascular causes for their clinical presentation were excluded. Patients were 
followed up at approximately 6 months after hospital discharge by telephone, clinic visits, 
or through calls to their primary care physician to ascertain the occurrence of long-term 
outcomes.  
Patient population: 
Prospective (warm pursuit) and retrospective (cold pursuit) surveillance 
approaches for identifying cases of ACS were utilized. When required, study 
investigators received approval from their local hospital ethics or institutional review 
board. For sites using active surveillance for case identification, verbal or written consent 
was obtained from patients to review information contained in their medical charts. 
Standardized definitions of all patient-related variables, clinical diagnoses, and selected 
hospital complications and outcomes were based on the American College of Cardiology 
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key data elements and definitions for measuring the clinical management and outcomes 
of patients hospitalized with ACS (Cannon 2001). 
Patients were defined as having an ACS if they had symptoms typical of ACS 
accompanied by at least 1 of the following: electrocardiographic changes consistent with 
ACS, serial increases in biochemical markers of cardiac necrosis (creatine kinase-MB 
fraction, creatine phosphokinase, or troponin), and documented coronary artery disease. 
Patients who died within 24 hours of hospitalization were enrolled in the study provided 
that the cause of death was related to ACS. 
Cardiogenic shock was defined as a systolic blood pressure of < 80 mm Hg and 
congestive heart failure (Killip class IV) occurring at any time during the acute 
hospitalization. The specific timing of shock onset was not collected, but patients 
presenting to the hospital with CS were differentiated from those developing shock in-
hospital by killip class IV on hospital presentation. Coronary revascularization was 
defined as the receipt of a PCI or CABG at any time during the index hospitalization.  
 Data collection: 
  Hospital records of patients with validated ACS were abstracted for demographic 
and clinical data, complications during hospitalization, electrocardiographic findings, and 
use of diagnostic procedures and therapeutic approaches. All medication usage was coded 
as present if it began either before or during the time of the index hospitalization. Data 
were stored and analyzed at the Center for Outcomes Research of the University of 
Massachusetts Medical School, Worcester, Massachusetts. 
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Data analysis: 
 Continuous variables were summarized by their means and standard deviations 
(SD) or medians as appropriate. Categorical variables were summarized by counts and 
percentages. Univariate comparisons of patient characteristics, presentation, treatments 
and outcomes data between patients with and without CS were carried out using the 
Wilcoxon rank sum or χ2 tests.  
  Short-term survival rates were estimated using the Kaplan–Meier method and 
log-rank tests were used for between group (CS present versus absent) comparisons.  
 The short term prognosis in each year was examined by calculating in-hospital 
and 30 day post admission case-fatality rates (CFRs). A logistic multivariable regression 
analysis was used to examine changes over time in the incidence rates of CS and in-
hospital CFRs, while controlling for potentially confounding demographic (e.g., age, sex) 
and clinical (e.g., prior comorbidities, ACS type) prognostic factors. These variables were 
considered as potential confounders based on univariate analyses and the findings of 
previous research. The Hosmer-Lemeshow goodness-of-fit test was used to examine the 
adequacy of our logistic regression models. 
 
Unadjusted and multivariable adjusted Cox proportional hazards models were 
employed to determine factors associated with an increased risk of dying in the hospital 
among patients who developed CS while controlling for potentially confounding 
prognostic characteristics including demographics, medical history, and clinical 
presentation. Given the nonrandomized nature of the present study, and the caveats and 
difficulties involved in the interpretation of any multivariable-adjusted estimates of 
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association, we did not control for the hospital use of cardiac treatment approaches in our 
regression analyses in which hospital survival status was the key outcome.  All analyses 
were performed with STATA version 11.0 (Stata Corporation, College Station, TX, 
USA).  
3.3 Results 
 
Baseline Characteristics  
The study population consisted of 65,119 patients with an ACS enrolled in 
GRACE between 1999 and 2007, of whom 4.6% (n=2,992) developed CS during their 
index hospitalization for an ACS. Compared to patients without CS, patients with shock 
were more likely to be older (6 years on average), to be women, and to have a prior 
history of diabetes, chronic heart failure, renal insufficiency, and stroke. Patients with CS 
were more likely to have a higher pulse rate, an STEMI, cardiac arrest, and lower systolic 
blood pressure compared to patients without CS at the time of hospital admission (Table 
3.1).  
 
 Treatment of Patients with Cardiogenic Shock 
 Cardiac catheterization was used in 57.3% and hospital revascularization was 
used in 47.4% of all patients with ACS complicated by shock. Revascularization was 
only used in 36.6% of elderly patients ≥75 years old compared to 55.3% of non-elderly 
patients with shock (p < 0.001).   
While ACS patients presenting with CS were less likely to undergo cardiac 
catheterization, once they were catheterized, they were more likely to undergo PCI or 
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CABG compared to patients without shock. Stent use was significantly lower in patients 
with shock who underwent PCI compared to patients who did not develop shock (88.0% 
vs. 93.2%, p <0.001) (Table 3.2).   
Pulmonary artery catheterization, intra-aortic balloon pumps , as well as cardiac 
supportive drugs , including  inotropes/pressors, were  used significantly more often  in 
patients with CS  compared to patients without shock (32.0%,29.0% and 79.8% vs. 3.7%, 
1.5% and 11.5% respectively, p <0.001) (Table 3.2)  
Thrombolytic therapy was administered more frequently to patients with shock 
compared to patients without shock (21.2% vs. 13%). Patients with CS were less likely to 
have received ACE inhibitors, aspirin, β-blockers, Ca-channel blockers, LMW heparin, 
and nitrates than patients without CS.  Of note, only Glycoprotein IIb/IIIa and 
unfractioned heparin were used more frequently among ACS cases complicated by shock 
compared to patients without shock (30.4 and 55.7% vs. 25.7% and 46.6% respectively). 
 
In-hospital case-fatality rates   
 The crude in-hospital CFR for patients with CS was 59.4% compared to 2.3% in 
patients without shock. Hospital mortality was markedly lower for patients who 
underwent coronary revascularization compared with those in whom a more conservative 
approach was adopted (45.3% vs. 72.0%, p <0.001). Patients developing CS during their 
acute hospitalization were at significantly higher risk for dying in-hospital compared to 
patients presenting to the hospital in shock (62.6% vs. 48.4%, p <0.001). 
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In examining differences in possible prognostic factors, in patients  who died, as 
compared with those who survived CS,  older patients, those with a history of selected 
comorbid conditions, , and those presenting with cardiac arrest were more likely to die 
after developing CS than respective comparison groups (Table 3.3).  
     
 Multivariable-adjusted survival regression models showed that older age, and a 
history of either myocardial infarction or diabetes mellitus were associated with an 
increased risk of dying among patients who developed CS. Models that included time of 
development of shock and in-hospital procedures showed that patients with CS who 
survived their acute hospitalization were significantly younger, presented with shock, and 
underwent PCI or CABG during hospitalization.  
  
 The crude 30-day CFR for patients with ACS complicated by cardiogenic shock 
was 59%. Significant univariate as well as multivariable adjusted predictors of an 
increased risk of dying during the 30 days following development of ACS for patients 
with CS were identical to the predictors of in-hospital mortality. 
 
Time trends in the incidence rates of CS 
 The crude hospital incidence rates of cardiogenic shock among patients with 
ACS decreased from 5.1% in 1999 to 3.6% in 2007 (Figure 3.1). Cardiogenic shock 
incidence rates adjusted for age, gender, medical history, clinical presentation, and length 
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of hospital stay showed significant declines over the study years (annual OR= 0.97, CI= 
0.95 , 0.98).  
 
Time trends in hospital case-fatality rates 
The crude in-hospital CFRs among patients with CS declined from 62% in 1999 
to 54% in 2006, with an  increase in these death rates in 2007  (Figure 3.2). In-hospital 
CFRs of shock patients adjusted for age, gender, medical history, clinical presentation, 
length of hospital stay, and study site showed significant declines during the  years under 
study  (annual OR= 0.94, CI= 0.90, 0.99).  
 
 
3.4 Discussion 
 
The results of our large multinational observational study provide insights into the 
magnitude, management, short-term mortality rates, and the characteristics of patients 
with an ACS likely to develop and survive CS. While our study showed declining short-
term mortality rates related to CS, the incidence rates of CS remained relatively constant 
during the years under study.   
Baseline Characteristics 
 Identifying patients at increased risk for developing CS and providing these high 
risk patients with urgent medical care is essential to decrease the risk of developing this 
serious complication among patients with an ACS.  Proper monitoring, risk stratification, 
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and aggressive intervention have been associated with improved survival among patients 
developing CS.6-9 Our study demonstrated that patients with ACS at high risk for 
developing CS were older, more likely to be female, diabetic, suffering from chronic 
heart failure, and were more likely to present to the hospital with ST-elevation 
myocardial infarction and cardiac arrest. Less than one quarter of all patients with CS 
presented to the hospital with CS, while the remained experienced shock at a later time 
during their acute hospitalization. 
Our results are similar to previously published findings from studies carried out in 
different settings including the Worcester Heart attack Study (WHAS), the GUSTO, and 
SHOCK trials6, 10, 11. 
 
Treatment of Patients with Cardiogenic Shock 
 Previously published results from clinical trials and observational studies have 
demonstrated that early mechanical revascularization in patients with CS was associated 
with lower mortality compared with initial medical stabilization (including intra-aortic 
balloon pump [IABP] counterpulsation and fibrinolytic therapy) followed by late or no 
revascularization7, 12. Based on these findings, the American College of Cardiology (ACC) 
and the American Heart Association (AHA) have elevated early mechanical 
revascularization for CS to a class I recommendation for patients younger than 75 years13, 
and a class IIA recommendation for those older than 75 years who are suitable 
candidates14. However, the availability of clinical practice guidelines does not necessarily 
translate to changes in “real world” practice15. The results of our study showing that more 
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than 40% of patients with CS were >75 years old is consistent with the previously 
published literature4, 6. Management of this high risk group, and appropriately selecting 
patients eligible for invasive management, remains an important clinical challenge.  
While patients with CS were less likely to undergo cardiac catheterization, once 
they were catheterized, they were more likely to receive PCI or CABG. This can likely be 
explained by the presence of larger myocardial infarctions, a greater frequency of multi-
vessel disease in these individuals, and because of their clinically unstable conditions. 
Patients with shock were also more likely to receive thrombolytics compared to patients 
who did not develop CS. Although the benefits of thrombolysis in patients with CS are 
less established compared to patients with AMI, this reperfusion approach has been 
demonstrated to reduce the risk of subsequent development of shock16 which is of 
significant importance considering that most patients develop CS after hospital 
presentation (>6 hours)6, 17. Patients with CS were less likely to receive evidence -based 
medications compared to patients without CS. Although these medications are associated 
with better outcomes in patients with ACS, most of them might aggravate hypotension in 
patients with CS; hence their lower utilization and they are often withheld until the 
patient is stabilized18. Patients with CS may benefit from selective β –blockers that 
improve cardiac contractility and increase cardiac output without noticeably affecting the 
heart rate or vascular resistance. Due to the lack of information on the exact timing of 
development of CS in our study, we were unable to determine the relationship between 
time of onset of Cs and the prescription of in-hospital medications or procedures. As 
expected, patients developing CS were more likely to receive cardiac supportive care in 
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the form of inotropic agents, vasopressors and intra aortic balloon pumps (IABP). Future 
studies should continue to monitor the use of various treatment approaches in this high 
risk patient population and identify patient groups less likely to be treated with evidence 
based treatments. 
 
 
In-hospital and 30-day case-fatality rates 
  
Cardiogenic shock remains the most frequent cause of in-hospital death among 
patients with an ACS. Historic case-fatality rates reported by previous studies have 
ranged from 50-80% 4, 7, 12, 19. However, and despite the persistently high death rates 
associated with CS, the prognosis for patients hospitalized with CS has improved 
considerably over the past four decades. Declines in mortality rates have been associated 
with advances in supportive care and a more aggressive approach to coronary 
revascularization7, 12.   
 As expected, and in agreement with the previous literature, patients with CS were 
significantly more likely to die in-hospital than patients who did not develop this 
complex hemodynamic complication (59.4% vs 2.3%). 
A number of nonrandomized studies suggest that PCI improves short-term 
survival in patients with CS with survival contingent on the successful establishment of 
coronary reperfusion. Uncontrolled studies of coronary artery bypass grafting show that 
this revascularization approach improves short-term survival among patients with CS 
when they are treated soon after shock has developed10. However, we were unable to 
assess the role of these interventional procedures because we could not determine 
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whether shock preceded or followed the use of these treatment strategies or to determine 
other reasons why certain patients received these therapeutic regimens and others did not 
(confounding by indication).  
  Consistent with the findings from previously published studies, older age, 
diabetes mellitus, history of myocardial infarction, and renal insufficiency were 
associated with an increased risk of in-hospital mortality among patients developing CS. 
However, developing CS during hospitalization and following hospital presentation 
remains associated with a highest risk of in-hospital mortality among patients with CS. 
Future studies should further explore factors associated with better monitoring of 
hemodynamic status at the time of hospital presentation and the accompanying risk of 
developing CS during hospitalization in this high risk population.  
 
Time trends in the incidence and in-hospital case-fatality rates of CS 
 
 It is difficult to compare the actual incidence rates of CS in published studies due 
to varying population characteristics, definitions of CS, and whether patients developing 
shock in the pre-hospital setting were included4, 20. The incidence of cardiogenic shock 
reported from previous studies has ranged from 3- 15%21, 22  depending on the study 
population characteristics. The overall incidence of CS reported in our study (4.6%) falls 
within this range. Moreover, we  demonstrated that the incidence rates of CS declined 
slightly over the period  under study ,consistent with findings from previous studies 
examining trends in CS incidence rates during the 2000s10, 23. Potential contributors to 
declines in the incidence rates of CS include the increased adoption of early 
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revascularization of patients with AMI,  increasing use of effective cardiac medications 
over time , and enhanced patient  monitoring efforts. 
 Results from our study show a clear declining trend in short-term mortality rates 
of CS between 1999 and 2006 with an increase in these death rates in 2007. While the 
reasons for this increase in short-term CFRs during our most recent study year remains 
unexplained,  it needs to be noted that our encouraging declines in the hospital death rates 
of patients with CS declined during the years under study when other covariates of 
prognostic importance were adjusted for. It might be considered surprising that global 
hospital mortality rates for shock have not decreased more significantly in a time period 
otherwise notable for increased use of improved techniques for PCI8, 24 (Refs) although 
global variations in use of these technologies and pharmacologies have been previously 
noted17.  
 
Study strengths and limitations 
Our study strengths include using high quality data and a large study sample to 
report on this very high risk population. Limitations of our study include the 
observational nature of the data and lack of information on the timing of development of 
cardiogenic shock as well as racial and socioeconomic data.  
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3.5 Conclusions 
 
The results of this study provide insights into the characteristics, management 
practices, and short-term mortality of patients with ACS complicated by CS. Although 
the magnitude of CS appears to be slowly declining, it still develops at a relatively high 
rate after ACS. The hospital death rate among patients with this complication remains 
high despite advances in management and declining rates over time. It remains of 
considerable importance to examine contemporary trends in the magnitude and short-
term outcomes associated with CS and to improve monitoring and risk stratification 
systems for identifying patients most likely to develop this devastating complication. 
 
Grant Support: The GRACE study is supported by an unrestricted educational grant 
from Sanofi-aventis to the Center for Outcomes Research, University of Massachusetts 
Medical School. Sanofi-aventis had no involvement in the collection, analysis, and 
interpretation of data, in the writing of this report, and in the decision to submit the paper 
for publication. 
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Table 3.1 Characteristics of Patients with an Acute Coronary Syndrome Complicated by Cardiogenic Shock 
Characteristic Patients with CS 
n(%) 
Patients without CS 
n(%) 
p-value 
 2,993(4.6) 62,134(95.4)  
Age, Mean (SD) yrs 71.01(12.5) 65.42(13.2) <0.001 
Age Group    
   18-54 368(12.4) 14685(23.8)  
   55-64 529(17.8) 14,760(23.8)  
   65-75 817(27.5) 16,102(26.0)  
   ≥75 1,262(42.4) 16,367(26.5) <0.001 
Female 1,143(38.3) 20,100(32.5) <0.001 
History    
   Angina 1,346(45.4) 32,608(52.7) <0.001 
   History of CAD 665(22.8) 19,098(31.3) <0.001 
   Myocardial Infarction 837(28.3) 18,710(30.3) 0.022 
   PCI 309(10.5) 11,045(17.9) <0.001 
   CABG 272(9.2) 7,746(12.5) <0.001 
   Current Smoking 1,475(50.1) 35,762(57.8) <0.001 
   Diabetes Mellitus 916(31.0) 15,388(24.9) <0.001 
   Chronic Heart Failure 516(17.5) 6,090(9.9) <0.001 
   Hypertension  1,768(59.9) 38,386(62.1) 0.013 
   Renal Insufficiency 325(11.0) 4,600(7.4) <0.001 
   Stroke/TIA 324(11.0) 5,070(8.2) <0.001 
Clinical Presentation    
   Pulse, mean(SD) 87.1(28.3) 79.1(20.8) <0.001 
   Systolic Blood Pressure 117.1(37.9) 142.5(29.0) <0.001 
   Cardiac Arrest 368(12.5) 933(1.5) <0.001 
   STEMI 1,909(63.8) 21,809(35.1) <0.001 
   NSTEMI 701(23.4) 20,690(33.3) <0.001 
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 Table 3.2 Treatment of Patients with an Acute Coronary Syndrome Complicated by Cardiogenic Shock 
Treatment Patients with CS 
n(%) 
2,993(4.6) 
Patients without CS 
n(%) 
62,134(95.4) 
p-value 
    
Procedures    
     Cardiac catheterization 1,706(57.3) 37,823(61.4)       <0.001 
     Any Coronary 
Revascularization 
1,408(47.4) 26,471(42.9) <0.001 
     PCI 1,190(40.1) 23,622(38.3)       0.053 
    of patients undergone PCI 
(%stent) 
977(88.0) 21,309(93.2) <0.001 
    CABG 272(9.2) 3,107(5.1)         <0.001 
Medications    
    GP IIb/IIIa 894(30.4) 15,798(25.7)         <0.001 
    Intra-aortic balloon pump 852(29.0) 892(1.5)         <0.001 
    Pulmonary artery catheter 945(32.0) 2,285(3.7)         <0.001 
    Pressors/inotropes 2,368(79.8) 7,030(11.5)       <0.001 
   Thrombolysis 627(21.2) 8,003(13.0)         <0.001 
   Adjunctive hospital medications    
   ACE inhibitors 1,595(53.9) 40,497(65.7)       <0.001 
   Aspirin 2,512(84.4) 58,130(93.7)       <0.001 
   β -blockers 1,656(56.1) 52,625(85.2)       <0.001 
   Ca channel blockers 368(12.6) 14,439(23.6)         <0.001 
   LMW Heparin 1,437(49.0) 36,156(58.9)       <0.001 
   Unfractioned Heparin 1,634(55.7) 28,544(46.6)       <0.001 
   Nitrates 1,916(64.7) 49,875(80.8)       <0.001 
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Table 3.3 Univariate Predictors of Hospital Survival for Patients with an Acute Coronary Syndrome Complicated by 
Cardiogenic Shock 
Characteristic Dead 
n(%) 
Survived 
n(%) 
p-value 
 1,775(59.4) 1,213(40.6)  
Age, Mean (SD) yrs 73.9( 11.6) 66.8(12.7) <0.01 
Age Group    
   18-44 23(1.3) 54(4.5)  
   45-54 116(6.6) 175(14.5)  
   55-64 239(13.5) 289(24)          
   65-75 460(26) 355(29.5)          
   75-84 644(36.5) 246(20.4)          
   ≥85 285(16.1) 85(7.1)         <0.01 
Female 733(41.5) 409(33.9)         <0.01 
Medical History    
   Angina 872(49.7) 472(39.0)         <0.01 
   CAD 419(24.2) 244(20.6) 0.024 
   PCI 177(11.0) 132(10.2) 0.48 
   CABG 170(9.7) 102(8.5)         0.24 
   Current Smoking 763(43.9) 709(58.9)         <0.01 
   Diabetes Mellitus 591(33.8) 324(26.9)         <0.01 
   Heart Failure 356(20.4) 160(13.3)         <0.01 
   Hypertension 1,090(62.5) 675(56.0)       <0.01 
   Renal Insufficiency 225(12.8) 100(8.3)         <0.01 
   Stroke/TIA 230(13.2) 94(7.8)          
Clinical Presentation    
   Presented with a Shock 322(18.7) 344(29.0)         <0.01 
   Cardiac Arrest 228(13.0) 140(11.7)         0.282 
   ST-segment Elevation 1,094(61.7) 814(67.1)       <0.01 
   Non-ST-segment Elevation 412(23.2) 288(23.7)         0.17 
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Figure 3.1 Time Trends in Crude Hospital Incidence Rates of Cardiogenic Shock 
Among Patients with Acute Coronary Syndromes  
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 Figure 3.2 Time Trends in Crude Hospital Case-fatality Rates for Acute Coronary 
Syndrome Patients with and without Cardiogenic Shock 
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Abstract 
Limited data are available describing the magnitude, clinical features, treatment practices, 
and short-term outcomes of comparatively young adults hospitalized with acute coronary 
syndromes (ACS). The objectives of this large multinational observational study were to 
describe trends in these endpoints among adults less than 55 years old who were 
hospitalized with an ACS between 1999 and 2007 (n=15,052). The overall proportion of 
young adult patients in our study population was 23% and the proportion remained 
relatively constant over the study period. Baseline demographic and clinical 
characteristics of our study sample did not change significantly during the years under 
study, whereas, the length of hospital stay declined by more than a day on average over 
the years under study. The overall in-hospital and 30-day multivariable adjusted In-
hospital and 30-day death rates declined by more than 30% (OR= 0.66, 95% CI= 0.60, 
0.74) during the years under study. The use of evidence based therapies proven to 
improve outcomes of patients with an ACS significantly increased over the study years. 
In conclusion, the results of this multinational study provide insights into the magnitude, 
changing characteristics, and short-term outcomes of comparatively young patients 
hospitalized with an ACS. Improving trends in short-term outcomes of comparatively 
young patients with an ACS during the near decade under study likely reflect enhanced 
primary and secondary prevention and treatment efforts. 
Keywords: acute coronary syndrome, young adults, time trends 
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4.1 Introduction 
 
 
Acute coronary syndromes (ACS) are a major cause of morbidity and mortality 
around the world.1 By 2020, ACS will be the leading cause of mortality worldwide2. 
While marked age-related differences have been observed in the risk of developing as 
well as the prognosis of ACS, few studies however examined the epidemiology of ACS 
in comparatively younger patients. This is exceedingly important in light of increasing 
trends in obesity, diabetes, and hyperlipidemia worldwide among young adults.3 The 
global registry of acute coronary events (GRACE) is the largest multinational prospective 
study designed to examine the characteristics, clinical management practices and 
outcomes of patients across the full spectrum of acute coronary syndromes4 (ACS). Using 
data from that study, we examined trends (1999-2007) in frequency rates, patient 
characteristics, hospital treatment practices, and short-term outcomes in comparatively 
young adults who had been hospitalized with an ACS. In light of global data of 
increasing prevalence of obesity and diabetes among young adults, we examined the 
trends in the proportion, treatment practices, and short-term outcomes of patients <55 
years old presenting with an ACS. 
 
4.2 Methods 
The study population consisted of patients <55 years of age who were hospitalized 
with a final diagnosis of ACS and enrolled in GRACE between 1999 and 2007. GRACE 
is designed to reflect an unselected population of patients with ACS, irrespective of 
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geographic region. A total of 113 hospitals located in 14 countries in North and South 
America, Europe, Australia and New Zealand have contributed data to this study. Full 
details of the GRACE methods have been published elsewhere.5,6 
Adult patients (>18 years old) admitted with a presumptive diagnosis of ACS at 
participating hospitals were potentially eligible for this study. Eligibility criteria were a 
clinical history of ACS accompanied by at least one of the following: 
electrocardiographic changes consistent with ACS, serial increases in biochemical 
markers of cardiac necrosis (creatine kinase-MB, creatine phosphokinase or troponin) 
and documented coronary artery disease. Patients with non-cardiovascular causes for the 
ACS clinical presentation, such as trauma or surgery, were excluded. The patients were 
followed-up at approximately 6 months by telephone, clinic visits or through calls to their 
primary care physician to ascertain the occurrence of several long-term outcomes. Where 
required, study investigators received approval from their local hospital ethics or 
institutional review board for the conduct of this study. Data were collected by trained 
study coordinators using standardized case report forms. Demographic characteristics, 
medical history, presenting symptoms, duration of pre-hospital delay, biochemical and 
electrocardiographic findings, treatment practices and a variety of hospital outcome data 
were collected. Standardized definitions of all patient-related variables, clinical diagnoses 
and hospital complications and outcomes were used. All the cases were assigned to one 
of the following categories: ST segment elevation myocardial infarction (STEMI), non–
ST segment elevation myocardial infarction (NSTEMI) or unstable angina. Data from the 
patients enrolled between April 1999 and December 2007 were used in this analysis.  
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The GRACE study period extending between 1999 and 2007 (a total period of 9 
years) will be divided into three equal time periods, 1999 to 2001, 2002 to 2004, and 
2005 to 2007. The three time periods will be used to examine near decade time trends, 
and as a mean to simplify the presentation of the results.   
  Chi-square tests for categorical variables and ANOVA for continuous variables 
were used to examine potentially changing trends in various demographic and clinical 
factors. The short-term outcomes in each period were examined by calculating in-hospital 
and 30-day case-fatality rates (CFRs) and trends in these endpoints were examined 
through the use of chi-square tests for trends. Logistic regression modeling was used to 
assess the significance of a near decade trends in short-term death rates while controlling 
for several potentially confounding demographic, medical history, and clinical 
characteristics of prognostic importance. Since length-of-stay declined over the study 
period, we included duration of hospital stay in our regression models. 
 
4.3 Results 
The demographic, clinical, and treatment characteristics of the study sample were 
shown in (Table 4.1). Approximately, one fourth of all patients enrolled in the study with 
a confirmed diagnosis of ACS between 1999 and 2007 was under 55 years of age. The 
proportion of patients <55 years presenting with ACS did not significantly change over 
the years under study (Figure 4.1). 
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 For ease of analysis and interpretation, we aggregated the individual study years 
into three groups [1999, 2000 & 2001 (earliest), 2002, 2003 & 2004 (middle), and 2005, 
2006 & 2007 (most recent)] for purposes of examining changing trends in the 
characteristics of patients hospitalized with an ACS (Table 4.1). In examining changing 
trends in baseline characteristics, the proportion of patients presenting with angina 
pectoris during the most recent years under study decreased markedly in the most recent 
years (57.0% vs. 35.5%) (p for trend <0.05). Patients in the most recent years under study 
were significantly more likely to present with a history of hypertension (49.3% vs. 44.6%, 
p<0.05), and were less likely to have a history of myocardial infarction (22.3% vs. 24.6%, 
p<0.05), or heart failure (3.0% vs. 3.7%) compared to patients hospitalized during the 
earliest years under study (all p for trend <0.05. The length of hospital stay declined 
significantly over the years under study (7.3 days vs. 4.5 days, p<0.05) (Table 4.1).   
 
There was a marked and steady increase in the use of effective medical therapies 
and revascularization procedures during the years under study (all p<0.01) (Table 4.2). 
The proportion of young patients hospitalized with an ACS and prescribed ACE 
inhibitors, B-blockers, statins, glycoprotein IIa/IIIb, or clopidogrel during hospitalization 
increased significantly during the years under study. Over time, the proportion of patients 
prescribed aspirin remained relatively constant while the proportion of patients prescribed 
calcium channel blockers decreased significantly.  While use of cardiac catheterization 
and PCI for revascularization steadily increased over the years under study (78.5% vs. 
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61.3%) and (55.3% vs. 37.9%) respectively, the use of thrombolysis and CABG steadily 
decreased (13.3% vs. 23.5%) and (3.7% vs. 4.7%) respectively (p for all <0.01) (Table 
4.2).  
 
Approximately one in every five patients <55 years of age hospitalized with an 
ACS developed a major cardiovascular complication during hospitalization. The 
incidence rates of atrial fibrillation, heart failure, cardiogenic shock, cardiac arrest, stroke, 
and major bleeding declined significantly between 1999 and 2007 among young patients 
hospitalized with an ACS (p for trend <0.01) (Table 4.3).  
 
Crude in-hospital and 30-day mortality among young patients admitted with an 
ACS declined significantly over the study period between 1999 and 2006 followed by  
rise in 2007  (Table 4.4).  
 
To more systematically examine trends in short-term death rates, we carried out a 
series of multivariable-adjusted regression analyses while simultaneously controlling for 
several potentially confounding prognostic factors (Table 4.5). The results of this analysis 
were consistent with the results of our univariate analyses, showing marked declines in 
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hospital and 30-day post-admission death rates over the study period by approximately a 
third. 
 
4.4 Discussion  
 
   In this large multinational study of patients < 55 years old who were 
hospitalized with an ACS between 1999 and 2007, the proportion of young adult patients 
remained constant over the near decade study period. These trends were observed 
concomitant with an increase in the frequency of previously diagnosed hypertension and 
a decrease in the frequencies of previously diagnosed angina pectoris, myocardial 
infarction, or heart failure over time, as well as in the presence of a persistently high rate 
of cigarette smoking. The complications and short-term death rates after ACS declined 
over the years under study, even after adjustment for factors known to affect these 
endpoints concomitant with the increasing use of evidence based therapies. 
Magnitude of Acute Coronary Syndromes in Young Patients 
 The overall proportion of young adult patients hospitalized with an ACS 
observed in our study is consistent with the relatively limited data available from 
observational studies examining ACS in young adults.1 Given the increasing prevalence 
of several cardiovascular risk factors among young adults around the world including 
obesity, hypercholesterolemia, and diabetes1-3 we wanted to examine trends in the 
proportion of young adults <55 years old presenting with an ACS in out multinational 
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study over time. Although we observed high rates of current smoking, and an increase in 
the proportion of hospitalized patients with a history of hypertension during the years 
under study, we observed declines in rates of medical history of angina pectoris, 
myocardial infarction, and heart failure, all while the incidence proportion of ACS did 
not significantly change over the years under study. 
In our study, we observed stable trends in the proportion of young adult patients 
presenting with ACS despite the increasing prevalence of cardiovascular risk factors. 
Increasing use of evidence based medications prior to admission that have been shown to 
reduce the likelihood of developing cardiovascular events in high-risk patients has been 
previously reported, including aspirin, ACE inhibitors/beta-blockers, and statin drugs.4,5 
Despite the non-randomized nature of our study that precludes any assumption of 
causality, we can with caution extrapolate that the increased outpatient prescribing of 
these medications may have exerted a positive effect on the overall incidence of 
developing ACS among young adults and potentially counter-balanced an increased risk 
factor burden among this population6. 
Baseline Characteristics of Young Patients with an ACS 
Previous studies have demonstrated that young patients with an ACS tend to be 
predominantly male, smokers, and hyperlipidemic7-12; we confirmed a male 
predominance among young patients hospitalized with an ACS. Although the rates of 
smoking observed in our study are high relative to contemporary studies involving 
patients of all ages, they are consistent with smoking rates reported in other investigations 
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involving comparatively young patients with an ACS.13,14 Our findings emphasize the 
strong pathophysiologic association between smoking, increased risk for coronary 
thrombosis, and the development of ACS in patients < 55 years of age.15-17  Due to 
missing data on hyperlipidemia in our study; we did not examine prevalence or trends in 
this cardiovascular risk factor.   
We observed a steady increase in the prevalence of hypertension in our study 
sample. This finding has been previously demonstrated in comparatively young patients 
with AMI from the Worcester heart attack study. Although the increasing proportion of 
patients diagnosed with hypertension may be related to enhanced surveillance, the 
increasing prevalence of hypertension may be related to the high and ever increasing 
population burden of obesity.18 
 
Changing Trends in Hospital Therapies 
Our findings confirm expected increases in the utilization of effective in-hospital 
treatments that have become the standard of care for patients hospitalized with an ACS 
during the recent decades.10, 11 Similar findings have been previously demonstrated by 
clinical studies examining patients with an ACS. Our findings also suggest a steady 
incorporation of guideline-supported primary and secondary prevention therapies into 
everyday clinical practice.19,20 
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 Changing Trends in Hospital Complications 
Twenty percent of patients < 55 years of age and hospitalized with an ACS 
developed a major cardiovascular complication during their index hospitalization. 
Although rates of major cardiovascular complications associated with ACS reported in 
our cohort were lower than rates that have been previously noted in populations including 
older patients, they paralleled those reported in other contemporary community-based 
studies examining young adult patient.12, 13 Declining rates of cardiovascular 
complications after ACS, especially when viewed in the context of increased use of early 
coronary revascularization strategies and evidence based medication, suggest that the 
early institution of effective inpatient therapies over time, and/or previously reported 
increasing baseline use of beneficial cardiac medications, may have contributed to the 
declining trends and lower rates of in-hospital cardiovascular complications observed in 
our patient population.27 
 
 Short-term Mortality  
 Relatively young patients presenting with an ACS to the GRACE hospitals had a 
favorable short-term prognosis. Our short-term death rates were consistent with those 
reported in prior population-based studies but slightly higher than the rates that have been 
observed in clinical studies involving patients < 50 years old with AMI.28 This is likely 
due to differences in age as well as variations in the socio-demographic and clinical 
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characteristics of patients participating in community-based studies relative to persons 
included in randomized clinical trials.  
 
Crude short-term mortality in our study sample declined steadily between 1999 
and 2006. The increase in crude mortality rates seen in 2007 has been previously reported 
by previous publications from GRACE and has been linked to the dropping of a number 
of medical centers in the final year of the study. However, short term mortality rates 
adjusted for potentially confounding prognostic factors demonstrated that rates declined 
by approximately one third compared to the early years under study. Improved public 
health awareness and increasing use of efficacious therapies for ACS have likely 
contributed to the decline in mortality observed.29-31 However, since the reported 
prevalence of hypertension, obesity, and diabetes has increased, and smoking rates 
remain high, an increasing burden of cardiovascular risk factors and comorbid disease 
among young patients hospitalized with an ACS may be responsible for the constant 
proportion of young adult patients presenting with an ACS over the years under study 
which calls into question whether or not changing demographics and clinical 
characteristics, such as increasing body mass, have contributed to the observed trends. 
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Study Strengths and Limitations 
The strengths of the present study include its multinational nature, its relatively 
large sample, its high quality, and its near decade long perspective. Our study also has 
several limitations. The non-randomized nature of our design precluded adjustment for 
differences in treatment practices over time and prevented us from establishing causality 
associations. Since the study design approach was not population based, we could not 
calculate population incidence rates. Lastly, because data on body mass index, and serum 
cholesterol levels were not complete, we could not examine trends in these modifiable 
risk factors. Lastly, lack of data on ethnicity and socioeconomic factors prevented us 
from examining their associations to the development and prognosis of ACS among 
comparatively young adults.  
         
4.5 Conclusions 
 
As expected, comparatively young patients with an ACS were predominantly 
males and smokers. Encouraging trends in hospital complications and short-term 
mortality were observed concomitant with increasing use of evidence based therapies.   
 
Grant Support: The GRACE study is supported by an unrestricted educational grant 
from Sanofi-aventis to the Center for Outcomes Research, University of Massachusetts 
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interpretation of data, in the writing of this report, and in the decision to submit the paper 
for publication. 
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Table 4.1. Baseline Characteristics of Young Patients with Acute Coronary Syndrome 
Overall and According to Time Period of Hospitalization 
 
                   Time Period 
 
Characteristic† 
Total Population 
(n=15,052) 
1999-2001 
(n=4,955) 
2002-2004  
(n=6,033) 
2005-2007 
(n=4,059) 
Age (mean, yrs) 47.8 (5.7) 47.7 (5.8) 47.8 (5.7) 47.7 (5.8) 
Age (years)     
       <40 10.2 % 10.5 % 10.2 % 9.7 % 
       40-44 12.7 % 13.5 % 11.7 % 13.3 % 
       45-50 26.7 % 25.3% 27.7 % 27.1 % 
       50-54 50.4 % 50.6 % 50.4 % 49.9 % 
Men 78.7% 77.9 % 79.1 % 79.0 % 
Medical History     
       Angina pectoris 44.5 % 57.0 % 40.4 % 35.5 % 
Myocardial infarction 23.1% 24.6% 22.3% 22.3% 
       Diabetes mellitus 17.0 % 17.0 % 16.7 % 17.6 % 
       Hypertension 46.6 % 44.6 % 46.5 % 49.3 % 
       Stroke 2.8 % 2.8 % 2.7 % 3.0 % 
       Heart failure 3.3 % 3.7 % 3.2 % 3.0 % 
       Current smoker 76.0% 76.5% 76.3% 74.7 % 
Prehospital delay (median, 
hrs)* 
2.5 2.5 2.5 2.4 
Length of stay (mean, days) 6.4 (6.6) 
 
7.3 (7.2) 
 
6.3 (6.4) 
 
5.6 (6.1) 
 
STEMI 
     
57.3% 57.5% 56.9 % 57.5 % 
     
† mean values (SD)  
 
* For patients reporting to the hospital within 48 hours of symptom onset 
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Table 4.2 In-hospital Therapies of Young Patients with Acute Coronary Syndrome 
Overall and According to Time Period of Hospitalization 
 
                   Time Period 
 
In-Hospital Therapies 
Total Population 
(n=15,052) 
1999-2001 
(n=4,955) 
2002-2004  
(n=6,033) 
2005-2007 
(n=4,059) 
     
       ACE/ARBs 64.2% 55.2 66.8 % 71.5 % 
 
       Aspirin 95.7% 95.7 % 96.0 % 95.5 % 
 
       Beta Blockers 89.7% 87.9 % 90.4 % 90.8 % 
 
       Calcium channel  
          blockers 
16.6% 20.7% 15.9 % 12.7 % 
 
       Statins 
 
73.4% 56.0% 79.5 % 85.6 % 
       Glycoprotein IIb/IIIa 33.1% 26.7% 37.1% 35.0% 
     
       Clopidogril 61.2% 23.8% 63.9% 77.0% 
     
       Thrombolytics 
 
18.9% 23.5% 18.8 % 13.3 % 
       Cardiac Catheterization 71.2 % 61.3 % 74.3 % 78.5 % 
 
       PCI 48.1% 37.9 51.4 % 55.3 % 
 
       Coronary artery bypass  
       Graft surgery 
  
4.5 % 4.7 % 4.8 % 3.7 % 
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Table 4.3 Risk of Selected Clinical Complications in Patients Hospitalized With an 
Acute Coronary Syndrome 
 
              Time Period 
 
Clinical Complication 
Total Population 
(n=15,052) 
1999-2001 
(n=4,955) 
2002-2004  
(n=6,033) 
2005-2007 
(n=4,059) 
Atrial fibrillation 2.40% 2.56% 2.42% 2.15% 
Heart failure 6.1% 7.4% 6.3% 4.4% 
Cardiogenic shock 2.10% 2.49% 2.02% 1.75% 
Cardiac Arrest 2.25% 2.17% 1.95% 2.78% 
Stroke 0.26% 0.37% 0.25% 0.15% 
Major bleeding 1.34% 1.72% 1.28% 0.97% 
 
 
94 
 
 
Table 4.4 Short-Term Death Rates in Patients Hospitalized With an Acute Coronary 
Syndrome 
 
Study Year In-Hospital Death Rates 30-Day Death Rates 
1999 2.12% 2.37% 
2000 1.63% 1.95 % 
2001 1.92% 2.19% 
2002 1.41% 1.75% 
2003 1.41% 1.69 % 
2004 1.52% 1.74 % 
2005 1.13% 1.32% 
2006 0.63% 0.84% 
2007 1.25% 1.73% 
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Table 4.5 Odds of Dying in Younger Patients Hospitalized with an Acute Coronary Syndrome 
 
 
 
 
Study Period 
Crude Odds of 
In-Hospital Death 
Multivariable 
Adjusted Odds of 
In-Hospital Death* 
Crude Odds of 
30-day Death 
Multivariable 
Adjusted Odds of 
30-day Death* 
 
1999-2001º 1.0 1.0 1.0 1.0  
2002-2004 0.89 (0.82-0.97) 0.83 (0.76-0.91) 0.93 (0.86-1.0) 0.83 (0.76-0.90)  
2005-2007 0.74 (0.67-0.81) 0.66 (0.60-0.74) 0.74 (0.68-0.81) 0.62 (0.57-0.69)  
*Adjusted for age, sex, length of stay, and history of angina, myocardial infarction, diabetes mellitus, hypertension, stroke, heart failure, or 
renal failure 
ºreferent period
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 CHAPTER V 
Conclusions 
 
5.1 Summary of Findings 
  
The main objective of this dissertation was to use the access to two well known 
international registries of ACS to answer three clinically important questions examining 
regional differences in disease management and outcomes, changing trends in ACS 
burden and complications, as well as identifying patients at higher risk of developing 
adverse clinical outcomes.  
In comparing regional differences in patient characteristics, disease management, 
and outcomes between the patients in the Arabian Gulf Area (Gulf RACE) to a large 
multinational unbiased sample (GRACE), we found that the average age of patients in 
Gulf RACE was strikingly a decade younger than GRACE. Patients in Gulf RACE were 
more likely to be male, with very high prevalence of smoking and diabetes, which might 
explain the early development of ACS. Patients in Gulf RACE were less likely to be 
treated with evidence based therapies compared to GRACE patients. Despite differences 
in patient characteristics and treatment practices, short-term mortality rates were 
comparable between ACS patients enrolled in these two registries, while higher rates 
short-term complications were observed among Gulf RACE patients. 
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    In examining cardiogenic shock as a serious clinical complication and the main 
cause of death in patients with an ACS, we found that 5% of patients in GRACE 
developed the serious hemodynamic complication. Patients developing CS were more 
likely to be older, female, have a history of diabetes, and heart failure, and present with 
ST-segment elevation. Patients with CS were less likely to receive revascularization and 
effective cardiac therapies. Despite declines over the study period in hospital mortality 
for patients with CS, case fatality rates remain really high at 59.4% compared to 2.3% in 
patients without CS. Although the magnitude of CS appears to be slowly declining, it still 
develops at a relatively high rate after ACS. 
In examining nearly decade changing trends in frequency rates, patient 
characteristics, hospital treatment practices, and short-term outcomes of comparatively 
young adults who had been hospitalized with an ACS in GRACE, we found that the 
overall proportion of young adult patients was 23% and the proportion remained 
relatively constant over the study period. Baseline demographic and clinical 
characteristics of our study sample did not change significantly during the years under 
study, whereas, the length of hospital stay declined by more than a day on average over 
time. The overall in-hospital and 30-day multivariable adjusted In-hospital and 30-day 
death rates significantly declined during the years under study. The use of evidence based 
therapies proven to improve outcomes of patients with an ACS significantly increased 
over the study years. Improving trends in short-term outcomes of comparatively young 
patients with an ACS during the near decade under study likely reflected enhanced 
primary and secondary prevention and treatment efforts. 
98 
 
 
Generally, we observed marked regional differences in ACS risk profiles, clinical 
management, and outcomes of patients with an ACS between the developing world 
represented by Arabian Gulf region, and multinational sample represented by GRACE. 
This finding is consistent with a large body of literature highlighting the continued need 
for international monitoring of ACS as a major cause of morbidity and mortality 
worldwide. We observed encouraging trends in the use of evidence based therapies which 
have likely contributed to the improving trends in the prognosis of ACS evidences by 
declines in mortality rates and rates of clinical complications associated with ACS.  There 
remains a large room for improving primary and secondary prevention efforts.  
 
 
5.2  Strengths and Limitations 
 
 
A particular strength of the dissertation was the use of data from two large 
multinational registries of ACS, which provided contemporary data on patients 
hospitalized with an ACS. The two registries used similar approaches to collect data on 
management practices and patient outcomes using similar standardized definition. Both 
studies used the American college of cardiology definitions of key variables, which 
represented a particular strength to our study when comparing the two patient populations. 
On the other hand, as with all observational studies, the GRACE and Gulf RACE project 
are subject to certain inherent limitations and potential biases.   
The GRACE study is the largest multinational registry to include the complete 
spectrum of patients hospitalized with an ACS. The Gulf RACE study represents the first 
99 
 
 
survey attempt in that region – otherwise under-represented in multinational studies of 
ACS- to include all patients hospitalized with an ACS in recent years. In both studies, 
standardized criteria were employed for defining ACS and hospital outcomes and 
rigorous quality control and audit measures were employed. ”Real-life” observational 
studies provide data on a heterogeneous population of patients that includes groups who 
are often under-represented in randomized trials. On the other hand, as observational 
studies, they are subject to certain inherent limitations and potential biases that must be 
kept in mind in interpreting the study results. Treatments were given according to 
individual physicians’ decisions and not through the use of standardized treatment 
protocols. While currently recommended criteria were utilized to characterize patients 
who were eligible for the receipt of the cardiac medications examined, due to our reliance 
on data obtained from medical records, questions might be raised about our ability to 
characterize patient’s eligibility status. Furthermore, we did not have information 
available on several patient associated characteristics (e.g., socioeconomic status, patient 
preferences) which may have confounded some of the observed associations. 
5.3 Implications and Future Research Directions 
 
Our results reinforce the need for the continued monitoring of ACS epidemiology 
with better representation of the developing world, being the major contributor to the 
projected future increase in ACS burden globally. Moreover, our results highlight the 
need for studies and programs with then primary focus of understanding causes leading to 
early development as well as triggers of ACS. Future studies should focus on the 
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development of dependable risk stratification systems for the early identification of 
patients at higher risk of developing adverse outcomes since the prompt receipt of proper 
therapies has been associated with better prognosis, and decreased rates of complications 
and mortality.     
In addressing some of limitations mentioned earlier in our study, future registries 
should collect more data on adherence to medication to enable more accurate analyses of 
associations between medications and patients outcomes. A population-based approach 
should be adopted whenever possible in designing new studies to fill out the gaps in our 
knowledge about population incidence rates and outcomes rates. 
Additionally, long-term follow up periods are required to detect benefits as well 
as adverse effects of therapies that develop over long periods of time and to assess long-
term outcomes. Future Studies should deploy systems for assessment of quality of life 
and patient satisfaction. Furthermore, and as our results showed relatively stable time 
trends when examining incidence rates of ACS development, better understanding is 
needed of the reasons behind these trends and the main coronary risk factors playing a 
role in the observed trends. More attention should be focused on monitoring modifiable 
risk factors to be able to design programs and intervention aiming at decreasing the 
burden on ACS around the world.    
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